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Current strategies to treat human abdominal aortic aneurysm (AAA) centre on 
maximal aortic size, which is at present the best-known predictor of AAA 
progression and impending rupture. However, the natural history of AAA remains 
poorly defined and most people with the disease die with their AAA from other co-
morbidities, rather than from their aneurysm. An AAA intervention strategy based on 
size alone most likely leaves some patients with small (‘low risk’) AAA unprotected 
from rupture, and others with larger (‘high risk’) AAA exposed to unnecessary 
surgery with its associated significant morbidity and mortality. There is thus an 
urgent need to identify a surrogate marker for AAA growth, progression and need for 
intervention.  
This Thesis presents an analysis of the role of interleukin (IL)-1α (IL-1α) as a 
potential future surrogate biomarker for AAA. It is the only research work to date to 
have looked into the role of IL-1α as a biomarker in AAA disease, correlating titres 
with different anatomical, morphological and patient-related factors. It is the first 
piece, in over 20 years of published literature, to have performed a robust 
methodology study on the measurement of IL-1a in serum samples using different 
techniques. A comparison study of commercially available immunoassays in the 
context of IL-1α has never been undertaken before, and we are the first to undertake 
one. Additionally the work on the natural history of AAA is one of the largest single-
centre cohort studies to analyse AAA growth in surveillance. 
The work covers three main areas: identifying why current strategies for monitoring 
AAA are ineffective, analysis of different serum processing methodologies and 
 
 
commercially available immunoassays used to measure IL-1α, and linking IL-1α to 
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Chapter 1: Introduction 
The purpose of this research work has been to assess the utility of IL-1α as a 
potential biomarker for human abdominal aortic aneurysm (AAA) progression. The 
work covers three main areas: identifying why current strategies for monitoring AAA 
are ineffective; analysis of different serum processing methodologies and 
commercially available immunoassays used to measure IL-1α; and the relationship 
between IL-1α and different AAA anatomical, morphological and patient-related 
factors. 
In order to conduct this work, it has been necessary to firstly ascertain an 
understanding of the natural history of AAA in our own patient population, and other 
biomarkers which have already been postulated to correlate with AAA disease. We 
have then used this knowledge to develop a rationale for why IL-1α may be a 
suitable candidate to identify those AAA which warrant treatment. This includes 
analysis of a large database of patients with AAA at Heart of England NHS 
Foundation Trust (HEFT). Following from this, we have recruited and tested serum 
samples from patients with AAA for IL-1α, having first undertaken a robust 
methodology study to validate sample processing and immunoanalysis techniques. 
Finally we have correlated this with various AAA patient and morphological factors. 
The Thesis is presented in segments to illustrate the progress of the research. The 
first part sets the scene, by identifying the on-going need for biomarker development 
in AAA through discussion of biomarkers which have been identified before, and 
their shortcomings. The second part describes why IL-1α should be a focus of 
interest in AAA disease. Thirdly, it addresses the methodology used to test IL-1α 
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using commercially available immunoassays The results from this methodology 
study are then presented, before a final analysis of IL-1α in patient recruits.  
Chapters 2 and 3 are an overview of the anatomy of the human aorta, its structure, 
composition and the biomechanics of blood flow through it as well as a description 
of human (AAA), their incidence, pathogenesis and treatment options. 
Chapter 4 describes biomarkers that have already been considered in the literature as 
potential AAA biomarkers. 
Chapter 5 provides a description of IL-1α and its role to date in the pathogenesis of 
cardiovascular disease. 
Chapter 6 presents the results from an analysis of the natural history of AAA in our 
own patient population at HEFT. 
Chapter 7 presents the methodology study from which IL-1α results were attained. 
Chapter 8 presents the results of Study 1, looking at serum IL-1α titres in patients 
with asymptomatic, infra-renal AAA size, morphology and growth rates. 
Chapter 9 presents the results from Study 2, looking at serum IL-1α as a marker of 
chronic inflammation in patients with asymptomatic AAA. 
Chapter 10 summarises the work and draws general conclusions from all of the 
studies, including ideas for potential future areas of research in the field. 
Thesis hypothesis and aims 
We hypothesise that IL-1α can be utilised as a surrogate marker for AAA progression 
in those with asymptomatic, infra-renal AAA. We speculate that IL-1α titres are 
elevated in those with AAA, and that these titres correlate with AAA size, 
morphology and patient-dependent factors such as co-morbidity.  
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The aims of this Thesis are to: 
1. Establish the natural history of AAA growth, identifying growth rates in our 
own patient population with AAA at HEFT. 
2. Investigate how best to measure IL-1α in a reliable, reproducible fashion 
using commercially available immunoassays. 
3. Investigate the relationship between IL-1α in a cohort of patients with 
asymptomatic, infra-renal AAA. 
4. Accumulate data on which to base future studies investigating IL-1α as a 
biomarker of AAA disease. 
Summary 
The proposed study is, to the best of our knowledge, the first to investigate changes 




Chapter 2: Anatomy, structure and function of the aorta 
Aims 
The aim of this chapter is to provide a basic understanding of the anatomy of the 
human aorta and its role as a conduit for blood in the body. Additionally, the 
composition of its wall and natural changes which occur with aging are described.  
Anatomy of the human aorta 
The human aorta is the largest artery of the body, arising from the left ventricle of the 
heart. It supplies oxygenated blood via unidirectional flow to all organs and 
peripheral tissues thus maintaining perfusion, and blood pressure, through its elastic 
properties. It has four distinct anatomical segments: the ascending aorta; aortic arch; 
descending thoracic aorta; and abdominal aorta. The ascending aorta begins at the 
aortic orifice of the left ventricle, which is the point of attachment of the cusps of the 
aortic valve. At this point, its normal diameter is approximately 30mm. It ascends 
approximately 5cm to the sternal angle, at which point it becomes the aortic arch, 
which then passes posteriorly in a curved fashion, to the left of the trachea and 
oesophagus. The thoracic aorta is a continuation of the arch arising at the level of the 
second sterno-costal joint. Its normal diameter is approximately 25mm, and it 
descends in the posterior mediastinum through the thoracic cavity to the diaphragm 
to the left of the vertebral column. 
The abdominal aorta begins as the level of the diaphragmatic aortic hiatus, at the 
level of the T12 and L1 vertebral discs and is approximately 13cm in length. The 
normal diameter for the abdominal aorta is 18mm to 20mm. It is a retroperitoneal 
structure lying anterior to, and against, the vertebral bodies as it passes just to the left 
of the midline. It terminates at the level of the L4 vertebra by bifurcating into the 
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paired common iliac arteries (CIA), which diverge and descend infero-laterally to the 
pelvic brim where they bifurcate into the internal and external iliac arteries.  
The branches of the abdominal aorta include unpaired visceral branches from its 
anterior surface (the coeliac trunk at T12 vertebra, the superior mesenteric artery 
(SMA) at L1 and the inferior mesenteric artery (IMA) at L3), paired visceral 
branches arising from its lateral surface (the renal arteries at L1 and the gonadal 
arteries at L2) as well as paired and unpaired parietal branches supplying the 
posterior abdominal wall, vertebral column and spinal cord.(1)  
Like all arteries, the aorta is comprised of three histologically distinct layers, the 
intima, media and adventitia. The intima is composed of a thin layer of endothelial 
cells (EC), sub-endothelial connective tissue and an internal elastic lamina. The 
media consists of smooth muscle cells (SMC) and extracellular matrix (ECM). It is 
the most prominent layer in large vessels such as the aorta, and is responsible for the 
pressurised transmission of blood from the heart. The outermost layer, the adventitia, 
is made of connective tissue which enfolds its own vascular supply (the vasa 
vasorum), as well as autonomic nerves (nervi vascularis) which supply and control 





Figure 1. Anatomy of the human aorta, including cross sectional representation 
of distinct histological layers.(3) 
Structure and function of the human abdominal aorta 
The aorta is the body’s largest elastic artery, serving as a conduit for the passage of 
oxygenated blood from the heart, through the entire arterial tree to supply distal 
tissues as well as an elastic reservoir maintaining blood pressure throughout the 
cardiac cycle.  
The structure of the aortic wall is dependent on the relative proportions of two major 
proteins which form the ECM: elastin and collagen, both of which are vital in 
determining aortic tensile strength and wall stiffness. In health, the aortic wall 






medial elastin layers decreasing from the thoracic aorta distally into the infra-renal 
aorta, where there is medial thinning in exchange for intimal thickening.(4) 
Elastin acts as the primary load-bearing component structure by forming organised 
cross-linked filaments using desmosine (DES) and isodesmosine (isoDES). These 
cross-links enable aortic stretch and recoil. Collagen within the aorta acts as the 
connective component, providing support and form through its abundance within the 
aortic ECM. Its fibres are stabilised by cross-links formed primarily by pyridinoline 
(PYR) and also deoxypyridinoline (DPD).(4) Although at least 29 different types of 
collagen are known to exist within the human body, the predominant aortic types are 
fibrillar types I and III, which account for >90% of all collagenous content, and then 
lesser amounts of types IV, V, VI and VIII.(5)  
During the natural aging process, particularly after the age of 50, there is a decrease 
in the total aortic collagen and elastin content, however their overall concentrations 
increase due to a global degeneration of aortic components which outweighs the 
degeneration of elastin and collagen. Relative to each other, elastin degradation 
exceeds that of collagen, so there is a relative increase in the collagenous content of 
the aorta, which contributes to increased arterial wall stiffness. Increased stiffness 
reduces compliance and induces an increase in pulse-wave velocity within the 
systemic circulation which alters normal pulse wave reflections in the cardiac cycle, 
with early return in late systole resulting in eventual ventricular hypertrophy by 
placing greater load on myocardial muscle as well as increasing central pulse load.(6)  
Summary 
The aorta is the human body’s main conduit for blood, providing the entire systemic 
circulation with oxygenated blood. Its structure allows for elastic recoil, and the 
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content of elastin and collagen within the aortic ECM account for its strength and 
form. The natural aging process alters the relative concentrations of these component 




Chapter 3: Human abdominal aortic aneurysms (AAA) 
Aims 
The aim of this chapter is to provide an understanding of the pathophysiology of 
AAA, including its epidemiology, the rationale for disease surveillance and 
screening, and interventions used to treat the condition. 
Incidence, pathogenesis and options for treatment 
The origins of the word aneurysm come from the Greek word ‘aneurusma’ meaning 
dilatation, or widening. Aneurysms can occur along the path of any vessel, but an 
abdominal aortic aneurysm (AAA) can be defined as a focal, irreversible dilatation of 
all three layers of the aortic wall exceeding 50% of the normal vessel diameter.(7) 
Although there is individual variability in vessel diameters, and ‘normal’ size can 
vary with age, gender and body habitus, the upper limit of normal in the human infra-
renal aorta is <30mm, and slightly larger for the supra-renal segment.(8,9) By 
definition, therefore, the abdominal aorta is said to be aneurysmal once it has reached 
at least 30mm in diameter. The majority of AAAs develop in the segment below the 
renal arteries, up to the aortic bifurcation into the paired common iliac vessels. 
Aneurysms at this point are known as infra-renal aneurysms. It has been postulated 
that the reasons for the predominance of infra-renal AAA over juxta- or supra-renal 
AAA, are due to changes in the composition of the aortic wall below the renal 
arteries, particularly the destruction of elastic lamellae in its medial segment.(10)  
Population-based screening studies suggest that the prevalence of infra-renal AAA is 
between 4.1 to 11.5% in European men ≥65 years, and 1.3% in women, and that the 
global incidence has continued to rise for the past four decades peaking in the eighth 
decade of life.(11–16) 
10 
 
A multitude of factors are implicated in the pathogenesis of AAA with increasing 
age, male gender, smoking and a positive family history for the disease as the 
strongest risk factors. Other associations include hypertension and possibly 
hypercholesterolaemia as well as a poorly defined genetic predisposition, with certain 
races (particularly Caucasians) being more susceptible to AAA development.(17–21) 
Women are less likely to develop AAA, but once they do, have an increased risk of 
aneurysm rupture and aneurysm-associated mortality.(22) 
In recent years there has been increasing interest in the biological properties of AAA, 
their composition and localised structural changes within the aortic wall which lead 
to expansion and rupture. Histopathologically, AAA are characterised by the loss of 
elastin and collagen from the media resulting in reduced vessel wall compliance and 
tensile strength. The proportional losses of elastin are greater than that of collagen 
however, and studies suggest that there is an increase in cross-link formation in old 
collagen in aneurysmal disease, with a defective collagen biosynthesis.(4) It is widely 
accepted that AAA represents a chronic inflammatory condition separate from 
atherosclerosis with which it nevertheless often co-exists due to shared risk factors.
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Microscopically, nearly all AAA are characterised by some degree of inflammation, 
with the degree of inflammatory infiltrate, containing large numbers of activated 
macrophages and T-cells within the media and fragmentation of the elastic lamellae, 
correlating with AAA size.(23)  
Atherosclerosis as a causative risk of AAA 
Atherosclerosis is thought to result as a ‘response to injury’ from substances such as 
oxidised low-density lipoprotein (LDL), by-products of cigarette smoking, diabetes 
and hypertension which elicit localised inflammatory reactions in vessel 
walls.(24,25) The initial lesions are fatty streaks, which are focal increases of 
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lipoproteins within the intima.(26) These fatty streaks are clinically asymptomatic, 
and can either involute or progress to fibrous plaque formation. They originate from 
blood-born monocytes which then differentiate into macrophages, engulfing sub-
intimal LDL, particularly small density LDL, remnant lipoproteins and 
lipoprotein(a). In doing so, they take on an engorged, foamy appearance, giving rise 
to the name ‘foam-cells’. Accumulation and progression of foam cells results in 
plaque formation (Figure 2).(27) 
 
Figure 2. Pathological progression of atherosclerosis.(28)  
There are two predominant schools of thought as to why atherosclerosis is important 
in the pathophysiology of AAA.  One theory is that environmental and genetic 
factors result in aortic atherosclerosis. Resultant remodelling, intimal thrombosis, and 
pro-inflammatory cytokine release stimulates secondary matrix degradation and 
adventitial inflammation to promote AAA development. The second is that 
environmental and genetic stimuli directly affect the vessel intima leading to 
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adventitial inflammation which directly causes AAA formation. Atherosclerosis 
formation then occurs as a secondary local event. 
The vascular inflammatory response 
In normal circumstances, vascular endothelial tissue is resistant to leukocyte 
adhesion. In the presence of pro-inflammatory stimuli however, there is endothelial 
expression of adhesion molecules resulting in attachment of monocytes and 
circulating lymphocytes. The mediators involved in cell-adhesion include P-selectin, 
E-selectin, intracellular adhesion molecule- (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1), which are present in endothelial cell walls.(26,29) 
Chemoattractants such as oxidised-LDL (oxLDL), Lp(a), monocyte chemoattractant 
protein (MCP-1), IL-1 and TNF-α allow sub endothelial migration of monocytes and 
T-lymphocytes. Studies have demonstrated that deficiency in MCP-1, or its receptor 
CCR-2, in mice significantly reduces atherosclerotic lesion development, suggesting 
that MCP-1 may be the most important chemoattractant factor in the disease process. 
Within the intima, monocytes mature into macrophages under stimulus from 
macrophage colony-stimulating factor.(30,31) 
Although the natural history of AAA remains poorly understood, in broad terms it is 
of gradual aortic expansion over time until rupture occurs. Unfortunately, most 
AAAs remain asymptomatic until rupture, which is fatal in up to 85% of cases.(32) 
Mortality from ruptured AAA remains a significant cause of death, accounting for 
approximately 2500 deaths in men aged ≥60 in England and Wales per year, or 2.5% 
of all deaths in males in that age group.(33,34) These figures are expected to reduce 
though, due to the advent of a national UK-wide NHS AAA Screening Programme 
(NHS-AAA-SP) in 2013, which should mean that patients with the disease are 
detected early and monitored closely.  At present, the best-known predictor of AAA 
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rupture is considered to be maximum anterior-posterior diameter (MAPD), however 
as noted above, other factors may be equally or even more important in certain 
patients. Studies suggest that the 5-year risk of rupture in AAA < 50mm is 5%, 50 to 
60mm is 25%, 60 to 70mm is 35% and in AAA>70mm is 75%. The UK Small 
Aneurysm Trial (UKSAT) and The Veterans Affairs Aneurysm Detection and 
Management (ADAM) Study have shown that the risk of rupture in AAA less than 
55mm MAPD is small at approximately 1% per year and that routine surgical 
intervention in asymptomatic AAAs less than 55mm confers no benefit.(35–38) 
UKSAT: recruited 1090 patients with small (40 to 55mm) AAA and randomised 
them into early open aneurysm repair (OR) or an ultrasound (US)-based surveillance 
programme. There was a short term survival disadvantage in those undergoing OR 
but no significant difference in mortality between groups at 2, 4 and 6 years of 
follow-up.(36) 
ADAM: recruited 1136 patients with small (40 to 55mm) AAA and also randomised 
them into early OR or an US-based surveillance programme, with OR being offered 
when the AAA reached >55mm. ADAM concluded that early OR of small AAA did 
not increase long-term survival and that deferring OR of small AAA until they had 
reached 55mm did not increase operative mortality.(37)  
The (changing) epidemiology of AAA  
In its 2008 publication ‘Fact file: Abdominal Aortic Aneurysms’, the British Heart 
Foundation stated that ‘‘Ruptured aortic aneurysms are the 13th commonest cause of 
death in the UK, responsible for 12,000 deaths per year……The incidence of both 
AAA and ruptured AAA continues to increase year on year.’’(39) 
14 
 
In fact, the incidence of ruptured AAA has reduced significantly in the UK in recent 
years and continues to do so.(40) Although this reduction pre-dates the NHS-AAA-
SP it still seems sensible to detect AAA as early as possible in the hope that lifestyle 
advice and medical treatment will not only prevent AAA disease progression, so 
reducing the numbers of patients requiring intervention, but also reduce the high rates 
of non-AAA related cardiovascular morbidity and mortality observed in this patient 
population. 
One problem with the NHS-AAA-SP is that on reflection, given the changing 
epidemiology, the decision to screen at 65 years (which was based on historical data) 
may have been incorrect. In fact, at this relatively young age far fewer AAAs are 
being detected than was anticipated, raising questions of the cost-effectiveness of the 
programme as it currently operates. In addition to formal screening, the increasing 
use of radiological investigations for other pathologies means that AAA are being 
increasingly identified as incidental findings.(40,41)  
It can therefore be argued that the current problem with AAA is not primarily that 
they rupture (in fact the observed rupture risk is quite low, and through early 
detection and intervention is likely to reduce further still in at-risk patients), but the 
excess non-AAA related cardiovascular morbidity and mortality seen in this patient 
group, irrespective of whether they have intervention or not. 
With the advent of endovascular aneurysm repair (EVAR) it was suggested that the 
MAPD intervention threshold for AAA repair, which (rightly or wrongly) currently 
stands at 55mm, might be reduced on the grounds that: 
1. EVAR is associated with less 30-day morbidity and mortality than OR 
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2. By waiting until the AAA were ‘large’ (MAPD >55mm), the ‘window of 
opportunity’ for EVAR might close through the loss of anatomical suitability 
In order to test this hypothesis, the Comparison of Surveillance versus Aortic 
Endografting for Small Aneurysm Repair (CAESAR) Trial recruited 360 patients 
with small (MAPD 41 to 54mm) AAA and randomised them to early EVAR or US-
based surveillance.(42) The investigators reported no significant advantage to early 
EVAR and suggested that, in fact, less than one in six patients managed with 
surveillance might subsequently become unsuitable for EVAR.  
With advances in stent-graft design this number will most likely fall further still. 
More recent studies have also suggested that although small AAA (MAPD <54mm) 
may be anatomically better suited to EVAR, early repair does not translate into 
improved clinical outcomes.(43) 
At the present time, therefore, there is no indication to routinely repair asymptomatic 
AAA less than 55mm in MAPD either by OR or EVAR. 
Importantly, although it is widely assumed that patients with AAAs exceeding 55mm 
benefit from routine OR or EVAR, and although that is likely to be true for selected 
patients, there is at present no data from randomised controlled trials (RCTs) (level 1 
evidence) to support such a contention. Unfortunately, it seems unlikely now that 
such RCTs will ever be performed, and many would view that as a missed 
opportunity. 
As the majority of AAAs remain asymptomatic, at present, AAA size (specifically 
MAPD) is by far the most commonly used surrogate for disease progression and 
rupture risk. However, the natural history of AAA remains poorly defined, and most 
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people with AAA die with their aneurysm from other co-morbidities, rather than 
from their aneurysm. 
AAA surveillance: rationale 
In the UK, the great majority of asymptomatic AAA less than 55mm in MAPD are 
entered into an US-based surveillance programme and offered, so-called, best 
medical therapy (BMT) comprising advice and help on smoking cessation; statin 
therapy to lower cholesterol and for their anti-inflammatory properties; control of 
hypertension; and anti-platelet agents to reduce the risk of thrombotic 
complications.(44) 
Data from UKSAT suggest that small AAA (MAPD <40mm) can safely be offered 
US at 24-monthly intervals and those with AAA with MAPD between 41-45mm an 
annual US. Patients with AAA approaching 55mm in MAPD who are being 
considered for OR or EVAR should probably be offered 3-6 monthly US scans as the 
larger the AAA, in general, the more likely it is to expand.(36,45) 
HEFT utilises the following MAPD-driven US-based surveillance protocol: up to 
39mm - annual scan, 40-49mm - 6 monthly scan; and 50-55mm - 3 monthly scan. 
Once the AAA exceeds 50mm MAPD on US, the patient is usually referred onto a 
vascular surgeon for further investigations, including CT angiogram (CTA) and 
cardiopulmonary exercise testing (CPEX)) pending an MDT decision, collaboratively 
made by vascular surgeons, interventional radiologists and anaesthetists, on whether 






Evidence for AAA screening 
Several RCTs have suggested that population US-screening for AAA for men aged 
65 years and above is a cost-effective means of reducing AAA-related deaths 
although a reduction in all-cause mortality has been less convincing. 
The Multicentre Aneurysm Screening Study (MASS): recruited 67,800 men aged 65-
74 years and randomly allocated them to an offer, or no offer, of US-based 
screening.(46) In those offered screening, 80% attended and in those that attended, 
AAA (defined as MAPD > 30mm) were detected in 4.9%. In the group offered 
screening and then considered for open surgery (OR) when the AAA exceed 55mm, 
or became symptomatic or had a growth rate >10mm/year, there was a significant 
reduction in AAA-related mortality, although all-cause mortality was not 
significantly different between the two groups.  
The Viborg Vascular (VIVA) Screening Trial: was of similar design to MASS and 
also reported an AAA detection rate of about 4% together with a significant 
reduction in AAA-related deaths, but no significant decrease in all-cause mortality, in 
those offered screening.(47)  
The NHS-AAA-SP was first established in 2009 and by 2013 it was the intention to 
be able to offer all men in the UK an abdominal US to confirm or exclude a diagnosis 
of AAA as they reach their 65
th
 birthday. 
Those found to have small AAA (MAPD 30-44mm) are offered an annual repeat US; 
those with AAA of MAPD 45-54mm 3-monthly US; and those with AAA of MAPD 
>55mm are referred to specialist vascular services for consideration of repair.(48)  
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A Markov model, based on UK MASS trial data, has been used to predict an 
anticipated 1749 saved ruptures and 1236 AAA-related deaths prevented after 30 
years of the screening programme being implemented.(48)  
However, it is apparent that these estimates, and so the screening protocol itself, may 
need to be reconsidered in the light of the lower than expected screening acceptance 
and AAA detection rates. 
Intuitively, population screening for AAA seems a good idea. However, until such 
time as we have a better understanding of the (changing) epidemiology and natural 
history of the condition and can, therefore, better identify those patients who would 
benefit from OR or EVAR, there is a real risk that national AAA screening in its 
present form may afford no overall (cost)-benefit, even cause net harm, and represent 
a sub-optimal use of already stretched healthcare resources.(36,49,50)  
Intervention for AAA: Choosing between open aneurysm repair (OR) and 
endovascular aneurysm repair (EVAR) 
At present patients are offered treatment if they are symptomatic, usually due to 
pressure effects of the AAA on adjacent structures, have complications such as distal 
limb ischaemia from embolisation of the intra-luminal thrombus (ILT), a rapidly 
expanding AAA ( often defined as an increase in MAPD >5mm per year) or present 
with rupture. However, the most common reason for intervention is that an AAA has 
reached the threshold size of 55mm. Patients with AAA deemed to require surgical 
intervention can be offered OR or EVAR.  
OR involves laparotomy, aortic exposure and cross-clamping above and below the 
AAA. The AAA is then opened and a prosthetic graft sutured in place to replace the 
diseased segment. As noted above, the operation is associated with a significant risk 
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of mortality and major morbidity (5-10%). However, if patients survive the surgery, 
protection against future AAA-related complications is verging on complete. 
EVAR involves insertion of a stent-graft into the abdominal aorta via the femoral 
arteries and avoids laparotomy and aortic cross-clamping. Not surprisingly, therefore, 
the EVAR-1 and EVAR-2 RCTs showed that EVAR is associated with a highly 
significant reduction in short-term (30-day) morbidity and mortality. However, for 
reasons that are not entirely clear, as soon as 6 months after intervention, the 
apparent survival advantage for EVAR has disappeared. Furthermore, the durability 
of EVAR has been called into question as a significant proportion of patients require 
further interventions for complications such as endoleaks and graft occlusion.(51,52) 
So, whereas a patient who has undergone successful OR can be discharged from 
follow-up, those who have undergone EVAR need to be re-entered into a life-long 
US-based surveillance programme aimed at detecting and correcting graft related 
problems before they become symptomatic. This adds significantly to the costs of 
EVAR and means that the long-term safety and effectiveness of EVAR depends 
heavily on patients’ compliance with a well-resourced, life-long post-operative 
surveillance programme. One suspects that neither of these conditions is universally 
met for all patients in hospitals offering EVAR.  
Endoleaks: biomechanical and biological significance  
Endoleak is a complication of surgery unique to EVAR and refers to persistent flow 
within the AAA sac despite graft deployment; five types are described:(53) 
 Type 1: loss of haemostatic seal between the graft and the vessel wall 
 Type 2: residual filling from feeding collateral vessels around the graft; for 
example, IMA or lumbar arteries 
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 Type 3: mechanical defect in the graft such as fabric tear or limb dislocation 
 Type 4: graft material porosity 
 Type 5: continued expansion of the AAA sac despite the absence of 
radiological evidence for endoleaks types 1 to 4 
The EVAR-1 RCT reported an endoleak incidence of 22%, of which 35% required 
secondary interventions to exclude aneurysm perfusion within 3 years of EVAR, 
whilst a systematic review reported that 17.5% of all EVARs showed evidence of 
endoleak at 30 days, which increased to 21.3% by 12 months.(51,54)  
All endoleaks except Type 2 and Type 4 are considered to usually require further 
(urgent) intervention which is often endovascular but may require conversion to open 
surgery. Type 4 endoleaks often subside over time without intervention. Many Type 
2 endoleaks also spontaneously resolve due to eventual thrombosis of the feeding 
vessels. However, such endoleaks should be actively monitored and if the AAA sac 
continues to expand, many surgeons would advocate intervention.(53) 
As well as re-exerting biomechanical stress on the AAA sac, the presence of an 
endoleak reconnects potentially biologically active ILT with the systemic circulation. 
Both seem likely to affect the outcome of treatment, not only in terms of local AAA-
related complications, but through the re-emergence of a systemic, pro-inflammatory 
diathesis.  
To date the literature has reported increasing interest in better understanding changes 
in circulating levels of biomarkers as an alternative to US-based surveillance of 
endovascular stent-graft failure after EVAR, with serum D-dimer levels reported as 
being elevated in those with unstable type-1 endoleaks.(55) 
Operative mortality: a cause for concern 
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It perhaps goes without saying that for the repair of asymptomatic AAA (especially 
those detected through screening) to be a net saver of lives, and so an ethically and 
clinically appropriate treatment strategy, the morbidity and mortality associated with 
OR and EVAR must be kept as near to zero as possible. Worryingly, recent data 
suggest that the mortality associated with AAA repair in the UK is not as low as it 
could, or should, be. 
The first VASCUNET data report (2007) compared AAA surgical outcome data from 
several European countries and identified the UK as having one of the highest 
mortality rates (7.9%, compared to a European average at 3.5%).(56) 
While this disparity might be related at least in part to the fact that in the UK AAA 
surgery is usually reserved for larger AAA, as well as differences in the accuracy of 
reporting between different countries, the report raised sufficient concern for the 
Vascular Society of Great Britain and Ireland (VSGBI) to introduce an AAA Quality 
Improvement Programme (QIP). 
This has further fuelled the debate over whether AAA surgery should be further 
concentrated into a smaller number of high-volume centres; encouraged participation 
in the National Vascular Database (now Registry)(57); and has driven QIP strategies 
to try to reduce the mortality associated with elective infra-renal AAA repair to 3.5% 
by 2013.(58)  
With the increasing use of EVAR one could argue that this reduction in mortality 
would have occurred anyway and many believe that a mortality of 3.5% is still too 
high given that we are operating on an asymptomatic, increasingly screen-detected 
condition of uncertain natural history. 
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The observation that a growing number of repairs are being performed in 




Chapter 4: Biomarkers and their role in AAA disease  
AAAs typically remain asymptomatic and undetected until complications arise; most 
commonly rupture, which is associated with a high risk of mortality. Several RCTs 
have suggested the risks of surgical intervention outweigh the benefits in patients 
with AAA <55mm MAPD. Although at present, MAPD is probably the best 
predictor of rupture risk as it reflects degeneration of the aortic wall and as such acts 
as a surrogate marker of impending rupture. An AAA intervention strategy based on 
MAPD alone most likely leaves some ‘at risk’ patients with small AAA unprotected 
from rupture and subjects others with larger AAA to unnecessary surgery which is 
associated with significant morbidity and mortality. 
Improved understanding of the molecular mechanisms underpinning aneurysmal 
disease is vital to better clarify the pathophysiology of the disease process and target 
at-risk patients in a clinical and cost-effective manner. Although a number of 
potential biomarkers have been identified and investigated, to date, none can be 
considered sufficiently sensitive or specific to AAA as to be considered clinically 
useful. In this chapter, surrogate markers for AAA disease studied in the literature are 
discussed. 
Aims 
The aim of this chapter is to review the various biomarkers that have been 
investigated in the pathogenesis and progression of AAA disease as reported in the 
English-language scientific literature at the time of starting this work. 
Methods 
We performed a MEDLINE/PubMed database search looking for English-language 
articles using search terms ‘abdominal aortic aneurysm’, ‘AAA’, and ‘biomarker’ 
24 
 
and ‘inflammatory response’. The search was restricted at July 2015. From this, a 
more targeted search was performed where identified biomarkers and terms such as 
human AAA, abdominal aortic aneurysm, and EVAR were included amongst others. 
Further literature sources were identified following PubMed links and by cross-
referencing from the citations of major articles or by following those used in source 
studies. Articles relating purely to thoracic aortic aneurysms were excluded.  
Biomarkers in disease 
Biological markers, or ‘biomarkers’ can be defined as a ‘‘cellular, biochemical or 
molecular alterations that are measurable in biological media such as human tissues, 
cells, or fluids’’.(59) Increasingly however, the term is also used to refer to biological 
characteristics of processes which can be measured either as predictors of disease 
development, activity, natural history and progression, or response to therapy.(60) It 
has been suggested that biomarkers can be categorised into two groups: those which 
predict the onset of disease or can identify patients likely to become affected (so 
called ‘biomarkers of exposure’) and those which can be used to quantify, asses or 
monitor disease progression and response to therapeutic interventions.  
In order for a biomarker to be of any practical use it should ideally be easy to 
measure with commercially available assays and exhibit low variability in terms of 
when it is measured.
 
Additionally, the following criteria should also be met:(61) 
 It must be central to the pathophysiological process implicated in the disease 
 It must therefore reflect or be a very clear surrogate of that disease process 




 Those at risk with a higher value at baseline must become more prevalent as 
disease severity increases 
 The biomarker must predict progression 
 The biomarker must also be sensitive to intervention factors that are known to 
be effective  
Identifying biomarkers for a variety of disease processes has become an increasingly 
studied area in the field of translational research. In the context of AAA, to date 
MAPD has been used almost exclusively in clinical practice as the preferred 
surrogate marker of disease progression, even though it is well known that small 
AAAs are still capable of rupture and some very large AAAs remain asymptomatic 
until the patient dies of some other cause. Thus finding alternatives to MAPD 
remains an important area of AAA research, not only in terms of influencing clinical 
practice, but also as a means to identifying modifiable pathophysiological disease 
pathways.  
With respect to AAA, studied biomarkers include genetic polymorphisms and 
markers of proteolysis, inflammation, immune response, and thrombosis and 
fibrinolysis.(62)
 
Although a variety of potential biomarker candidates have been 
evaluated, few have been validated as clinically viable tests of AAA disease 
progression or response to surgery.  
The urgent need for an AAA biomarker 
From the discussion in Chapter 3, it is apparent that there exists an urgent need for a 
biomarker that can help determine which AAA are mostly likely to rupture so that 
pre-intervention screening and surveillance, intervention (OR and EVAR) and post-
intervention surveillance can all be conducted in the most clinically and cost-
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effective manner. With respect to AAA, potential biomarkers might include markers 
of proteolysis, or inflammation, but for widespread clinical application, ideally 
should be measurable in easily-collectable samples e.g.: serum or plasma, or 
calculated from radiological imaging techniques. 
Markers of proteolysis 
Proteolytic enzymes play an important role in the regulation and remodelling of the 
extra-cellular matrix, and hence also in the degradation of the aortic wall. This in turn 
promotes AAA formation, and subsequent rupture, by destabilising the aortic wall 
and its tensile strength. Matrix metalloproteinases (MMPs) are a group of such 
enzymes which have been shown to play a role in AAA disease, with histological 
studies of aneurysmal aortic tissue demonstrating elevated levels of MMP and 
decreased levels of tissue-inhibitor of metalloproteinases (TIMP) activity. MMPs that 
are considered important in AAA include MMP-1,-2, -3 and -9, cathepsins and serine 
proteases, but other enzymes include; chymase; tryptase; plasmin and tissue 
plasminogen activator (tPA).(63–68) 
Animal studies have shown that decreased levels of MMPs, particularly MMP-2,-9 
and-12, and increased TIMP preserves aortic wall elastin content thereby inhibiting, 
or at least controlling, AAA formation.(69)
 
The source of the elevated levels of 
MMPs and other associated proteases remains, as yet, undetermined, although there 
is some early evidence to suggest that AAA intra-luminal thrombus (ILT) may be a 
potential source.(70)
 
One small study has shown that ILT-load correlates with MMP 
activity and others suggest MMP-9 may have some potential in post-EVAR 
monitoring as levels have been shown to normalise following surgical repair. MMPs 
are unlikely however to be of value in diagnostics, as levels have not been found to 




Genetic markers   
Although poorly defined, it is widely accepted that there is a strong genetic 
component to AAA disease, with studies suggesting that up to 15% of AAA patients 
have a positive family history. The literature suggests that in the past few decades 
much work has been undertaken on genetic association studies in AAA using single 
nucleotide polymorphisms (SNPs) in biologically important genes of the ECM, 
cardiovascular and immune systems. Widespread population generalizability of 
results from much of this work has been limited however, due to small study sample 
sizes and a lack of reproducibility or replication across sample sets.(75)  
The more recent approaches of identifying the genetic basis of AAA are family-
based DNA-linkage studies and genome-wide genetic association studies, which 
have the potential of identifying the genetic basis of AAA. SNPs associated with 
AAA have already been identified in other large, multicentre trials and whole-
genome scans have suggested loci on chromosomes 19q13 and 4q31. Although there 
has been interest in the role of genetics in the development of AAA, the inherent 
problems of linking genetic susceptibility with the actual development of AAA in 
patients limits the role of genetic markers.(76–78)  
Markers of inflammation 
There is a body of evidence in the literature suggesting that patients with AAA have 
abnormalities within their inflammatory and coagulation profiles. As such, patients 
with the disease can be considered to be in a ‘pro-thrombotic, hypercoagulable, pro-
inflammatory’ state.(79–82) In addition, it has previously been shown that patients 
with AAA have abnormal baseline markers of coagulation and inflammation, and 
that these are attenuated in the immediate post-operative period, and normalise in 
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some (but not all) cases. Even when there is a reduction of such biomarkers to pre-
operative levels, they remain elevated when compared to controls.(83)  
Several groups have hypothesised that changes in serum markers of inflammation, 
coagulation and fibrinolysis play a significant role in the short and long-term 
mortality and morbidity observed after both OR and EVAR. Specifically, an 
association has been observed between abnormalities in the coagulation and 
fibrinolytic systems and adverse clinical outcomes, such as the systemic 
inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome 
(MODS) and acute respiratory distress syndrome (ARDS), all of which are 
expressions of an inappropriate generalised response to inflammatory stimuli and are 
associated with a significant (up to 80%) mortality.(84,85) 
In the elective setting, AAA repair is associated with a mortality and major 
complication rate of up to 5-10%. However, in cases of rupture mortality is 
disproportionately high relative to peri-operative haemodynamic instability. In 
modern practice, mortality and morbidity is more often the result of (prothrombotic) 
complications such as myocardial infarction (MI) and MODS, rather than from intra- 
and post-operative haemorrhage.  
It is hypothesised that this may be because patients with AAA are already in a 
‘primed’ hypercoagulable  state, a form of low-grade disseminated intravascular 
coagulation (DIC), which then escalates rapidly in response to the physiological 
changes (low blood pressure, hypoxia) associated with rupture. Although patients 
undergoing elective OR and EVAR may also exhibit such changes, the peri-operative 
physiological disturbance (and so the clinical consequences) are less severe.(85,86) 
This idea is supported by one study which demonstrated an association between 
elevated pre-operative serum thrombin antithrombin complex (TAT) and a post-
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operative rise in cardiac troponin-T (cTnT), yet most of the patients had no clinical 
cardiac symptoms or signs.(87) 
The proteolytic generation of elastin and collagen degradation products attracts 
circulating inflammatory cells such as macrophages and mononuclear lymphocytes, 
which then produce pro-inflammatory cytokines, chemokines and immunoglobulins 
to further perpetuate the remodelling process.(62,88–90) In normal circumstances, 
vascular endothelial tissue is resistant to leukocyte adhesion. In the presence of pro-
inflammatory stimuli however, there is endothelial expression of adhesion molecules 
resulting in attachment of monocytes and circulating lymphocytes. The mediators 
involved in cell-adhesion include P-selectin, E-selectin, intracellular adhesion 
molecule- (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which are 
present in endothelial cell walls.(26,29,91) Chemo-attractants such as oxidised-LDL 
(oxLDL), lipoprotein(a) [Lp(a)], MCP-1, IL-1 and TNF-α allow sub endothelial 
migration of monocytes and T-lymphocytes. Studies have demonstrated that 
deficiency in MCP-1 or its receptor CCR-2 in mice significantly reduces 
atherosclerotic lesion development, suggesting that MCP-1 may be the most 
important chemoattractant factor in the disease process.(30,31)
 
 
Work on the pathogenesis in AAA disease suggests that important markers of the 
inflammatory response include pro-inflammatory cytokines such as tumour necrosis 
factor-alpha (TNF-α), interleukin (IL-) 6 and 8, acute-phase proteins such as C-
reactive protein (CRP) as well as anti-inflammatory cytokines such as transforming 
growth factor (TGF)-β. Histopathological analysis of diseased aortas has shown focal 
abundance of such inflammatory cells compared to normal specimens. The difficulty 
in using such inflammatory markers as biomarkers of AAA progression is, of course, 






IL-6 is produced by many cells, including macrophages. On binding to its target 
receptors it acts on activated B cells, plasma cells, and T cells amongst others to exert 
proliferation, pro-atherogenic, stem cell differentiation and acute phase 
responses.(93) 
IL-6 has been described as one of the most important pro-inflammatory cytokines in 
the initiation and progression of the inflammatory cascade, and its role as a predictor 
of future cardiovascular events in clinically asymptomatic patients is well 
documented. In the context of AAA however, an association with IL-6 is less clearly 
established, although it is the cytokine most consistently described in AAA disease. 
In vitro studies have suggested that AAA may be a source of IL-6 with circulating 
levels higher in patients with the disease than in controls.(94,95) A prospective study 
looking at 360 patients with AAA found elevated IL-6 levels compared to a non-
diseased control population and found a correlation between increasing AAA size 
and elevated levels. Another smaller study found levels to be elevated in patients 
with AAA and a possible correlation with size.(82,96–100) Additionally, IL-6 levels 
have been found to correlate with aortic diameters in healthy subjects.(95,101,102) 
IL-8 
IL-8 is produced by macrophages, endothelial cells, monocytes and T-cells. On 
binding to its receptor, present on neutrophils, T-cells and monocytes it acts to 
promote pro-atherogenic, pro-inflammatory effects. Its over-expression in AAA has 
been reported, and there is also evidence to suggest that its source may be the ILT. 
Some studies also describe a significant correlation between plasma IL-8 and 
maximal AAA diameter; however results in the literature are conflicting. Some 
report  IL-8 levels to be significantly low in patients with large AAA and so its role 
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as a diagnostic tool, or as a reliable predictor of AAA progression has not yet been 
determined.(93,95,103–105) 
CRP 
C-reactive protein (CRP) is an acute-phase protein detectable in only trace amounts 
in the serum of healthy subjects, which rises rapidly in response to inflammation or 
physiological insult. In response to cytokine stimulus, particularly by IL-6, its role in 
AAA may be linked to its ability to activate monocytes, mediate endothelial 
dysfunction, induce a pro-thrombotic state and increase cytokine release.(106–109) 
Several studies investigating the role of CRP and highly-sensitive CRP (hs-CRP) in 
AAA disease have provided mixed results: animal studies have shown significantly 
increased CRP and hs-CRP levels in AAA models when compared to controls
 
and in 
men with small AAA compared to sex and age or race-matched controls. Others have 
suggested a correlation between CRP and the extent of AAA disease, with levels 
being higher in patients with symptomatic or ruptured cases. A few small studies 
have also shown some correlation between hs-CRP or CRP and aneurysm size, 
however others have found levels to be within normal limits, with no such 
correlation. Although CRP, or even hs-CRP, would make a potentially attractive 
biomarker of AAA disease, being commercially readily-available, relatively cheap 
tests that can produce reliable, reproducible results their inherent disadvantage is 
again the lack of sensitivity or specificity to AAA disease.(74,80,99,110–112)  
TGF-β 
TGF-β consists of a group of more than 30 proteins, and as such forms a 
‘superfamily’ group of cytokines which all play a role in cellular growth, 
differentiation, adhesion and apoptosis. It has been shown to down regulate 
inflammation and inhibit MMP-dependent proteolysis and animal studies have 
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suggested over-expression can slow the expansion of AAA, suggesting there may be 
a role for it in future pharmacological control of AAA progression.(113–115)   
TNF-α 
Tumour necrosis factor (TNF)-α is predominantly produced by macrophages and 
binds to its receptor, present on many cell-types, to act as a mediator within the 
inflammatory response by increasing neutrophil endothelial adhesion and inhibiting 
anticoagulatory mechanisms. It has been identified as an important mediator in AAA 
formation, with studies suggesting significantly elevated levels in AAA compared to 
matched-controls, increased expression of its converting enzyme, tumour necrosis 
factor-α converting enzyme (TACE), in human aneurysmal aortic segments and 
prevention of AAA development in animal studies where TACE was deleted, or 
blocked. The concern in using TNF-α as anything other than an identifier of active 
inflammation within patients with AAA is, of course, as with many of the above 
named markers of inflammation, that it is a general marker, that can be elevated or 
suppressed in many different pathologies, which limits its value as a tool to monitor 
the progression of AAA in patients.(100,116,117)  
Intraluminal thrombus as a biologically-active component of AAA 
Most AAAs contain intraluminal thrombus (ILT) as a result of endothelial injury, 
platelet activation, a prothrombotic diathesis and turbulent flow within the sac.(118) 
Thrombus contains high concentrations of MMPs, elastase and plasmin, which are all 
proteolytic enzymes capable of altering the structure, and so the biomechanical 
properties, of the aortic wall.(63,68) The proteolytic breakdown of elastin and 
collagen attracts circulating inflammatory cells such as macrophages and 
mononuclear lymphocytes which then produce pro-inflammatory cytokines, 
chemokines and immunoglobulins, thereby perpetuating the remodelling 
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process.(88,90) Thrombus volume has been shown to correlate with AAA growth 
and some authorities believe that thrombus burden may be a better predictor of 
rupture than diameter.(119–121) There is growing evidence to show intraluminal 
thrombus (ILT) is biologically active and contributes to AAA progression and the 
development of complications; it may also influence the response to treatment and 
could, as such, be measured to possibly predict those AAA that are more 
'biologically active' and therefore likely to result in clinical complications.(122,123)
  
Conclusions 
A number of potential biomarkers have been proposed but to date none can be 
considered sufficiently sensitive or specific to AAA disease to be clinically useful. 
However, there remains a strong argument to identify surrogate factors which could 
be used to quantify those with the greatest clinical need for operative intervention as 




Chapter 5: IL-1α and its role to date in the pathogenesis of disease 
Cytokines are small (less than 20kDa), soluble proteins involved in the inter- and 
intra-cellular transmission of cellular information. They are key molecular mediators 
of inflammation, and as such are cell-signalling molecules, released in response to a 
stimulus by a variety of cells to exert a diverse range of effects.(124) 
IL-1α is a member of the IL-1 ‘super-family’ of pro-inflammatory cytokines. IL-1 
was first discovered in the 1940s, when it was referred to as ‘endogenous or 
leukocytic pyrogen’, linking infection and inflammation to fever. It has since been 
found to have at least 11 members (IL-33, IL-36α, IL-36β, IL-36γ, IL-36Ra, IL-37, 
IL-38, IL-1β, IL-1RA and IL-18). This broad group of polypeptides can be sub-
divided into 3 sub-families (IL-1, IL-18 and IL-36) according to the length of each 
member’s individual precursor.(125) Members of the IL-1 sub-group function by 
causing pro-inflammatory effects, induction of other cytokines, and promote cell 
differentiation, proliferation and apoptosis.  
The members of the IL-1 sub-group include IL-1α, IL-1β, IL-33 and a naturally 
occurring IL-1 receptor antagonist (IL-1RA). IL-1α and IL-1β are produced by 
different genes but demonstrate high sequence homology, having 22% identical 
amino-acids.(126) Nevertheless, they remain distinct entities and are thought to exert 
different biological effects. The IL-1α precursor is cleaved predominantly by the 
membrane-bound protease calpain into its mature form, but some transformation can 
also take place via extra-cellular neutrophil proteases.(125)  
IL-1 is primarily produced by peripheral blood monocytes as well as specialised 
tissue cells such as macrophages in response to infection or tissue injury, although 
epidermal, epithelial, lymphoid and vascular tissues are also able to produce it.(126) 
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In health, interleukin-1 alpha (IL-1α) is not detectable within the circulation, being 
primarily an intra-cellular entity, found in the cytosol of cells, and on plasma 
membranes, but it may become so in certain diseased states.(127) Production of IL-1 
is regulated at several stages including transcription, translation pro-IL-1 cleavage as 
well as release. IL-1α is present in two isoforms: a precursor (pro-IL-1α), which has 
a molecular weight of 31-33kDa and a ‘mature’ 17kDa molecule. Once activated, 
mature IL-1α can be secreted from cells to trigger an inflammatory cascade after 
binding to IL-1 receptor type 1 (IL-1R1).(127–130) There is evidence to suggest that 
pro-IL1α acts as an alarmin molecule by initiating inflammatory pathways and, as 
such, is biologically active.(131) The wall of human aneurysmal aortas have been 
found to contain elevated levels of IL-1α, however it is as yet not known which 
isoform is biologically active in the AAA disease process.(104,128,132,133) 
Activation of pro-IL-1α occurs through membrane-associated calpain-mediated 
cleavage. Calpeptin is a synthetic calpain-inhibitor which acts to inhibit activation of 
pro-IL-1α into its mature isoform.(129,134–137) IL-1α acts by binding to the IL-1 
receptor type 1 (IL-1R1) to induce subsequent recruitment of IL-1 receptor accessory 
protein (IL-1RAcP) which triggers intracellular signalling resulting in the activation 
of nuclear factor κB (NF-κB) transcription factor and mitogen-activated protein 
kinases (MAPKs). These then act to cause downstream up-regulation of pro-
inflammatory cytokines such as IL-6, TNFα, chemokines and adhesion 
molecules.(138,139) Upon release, IL-1α is regulated via two receptors: a naturally 
occurring IL-1 receptor antagonist (IL-1Ra) which binds to IL-1R1 to inhibit IL-1α, 
and IL-1R2, which functions as a decoy receptor by failing to up-regulate 
downstream IL-1α signalling pathways as it lacks a signal-transducing cytosolic 
domain.(140) The IL-1α signalling receptor complex consists of IL-1R1 and IL-1 
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Receptor Accessory Protein (IL-1RAcP), and once bound to this, activated IL-1α 
phosphorylates IL-1 receptor associated kinase (IRAK) via links formed through 
myeloid differentiation factor 88 (MyD88). Phosphorylated IRAK then dissociates 
from the receptor complex and associates instead with TNF receptor associated factor 
6 (TRAF6), activation of which induces two further kinase pathways in a manner that 
is not yet fully understood. These two kinase pathways, the IkappaB kinase (IKK) 
complex, and the p38 MAPK act by inducing phosphorylation of IκB protein, 
causing its ubiquination and degradation (in the case of the IKK pathway) which then 
liberates NF-κB, enabling its translocation into cell nuclei where it induces target 
gene expression. The MAPK pathway, once activated, leads to activator protein-1 
(AP-1) transcription factor activation through c-Jun kinase (Jnk). Activation of IL-
1RI triggers multiple and sequential phosphorylations that result in nuclear 
translocation of transcription factor. Post receptor amplification is responsible for the 
potent effects of IL-1 signalling despite the relatively low expression of IL-1RI in 
cells.(141)  
IL1α in atherosclerosis and cardiovascular disease 
Atherosclerosis is a chronic, insidious disease process affecting the arterial wall, 
which becomes thickened over time, thus losing its normal functional abilities. 
Although any artery of the body may be affected, lesions typically manifest at vessel 
bifurcations or sites where there is turbulence in normal, laminar blood flow. Risk 
factors for the disease can be sub-grouped into constitutional factors: increasing age, 
male sex and a positive family history, or acquired: smoking, hypertension, diabetes 
and hypercholesterolaemia. Pathogenesis is the result of interplay between several 
mechanisms, including inflammatory, biochemical, metabolic and thrombotic events, 
although historically it was thought to be solely the result of lipid accumulation.(25) 
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Although no single inflammatory cascade is thought to directly result in 
atherosclerotic lesions, there is an emerging role for IL-1α in the development and 
propagation of the disease.  
There has been interest in IL-1 in the context of inflammation and cardiovascular 
disease. IL-1 is thought to play a part in atherosclerosis through vessel wall 
inflammation, leukocyte chemotaxis and adhesion and increased levels of IL-1 have 
been found within atheromatous plaques.(103,142–147) IL-1 may increase 
expression of MMPs leading to collagenous breakdown within plaques and 
instability. Studies in mice have shown an absence of IL-1β decreases the severity of 
atherosclerosis.(142,148) In the context of AAA, studies have shown that patients 
with aortic disease have elevated IL-1β titres.(89,94) One study has looked at the 
inflammatory activity of IL-1α and found that patients had an elevated titre which 
was reversed after EVAR.(137)  
As atherosclerotic lesions form, localised ischaemia results in necrosis and the 
release of intra-cellular IL-1α. This then binds to its receptor on adjacent 
macrophages and epithelial cells to induce a response such as localised infiltration of 
neutrophils and monocytes.(133) Additionally, IL-1α stimulates the production and 
release of endothelial adhesion molecules and proteases as well as inducing the 
release of messenger cytokines such as IL-6, which in parallel, then stimulate hepatic 
release of acute-phase reactants such as CRP.(26) Both IL-6 and CRP have been 
found to be elevated in patients with advanced atherosclerotic plaques.(149,150) 
Direct monocyte activation by IL-1α also increases endothelial cell (EC), monocyte, 
and MMP-9 production and subsequent leukocyte infiltration.(151) MMP-9 is an 
enzyme involved in elastin degradation, and has been shown to correlate positively 
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with aortic stiffness, causing hypertension, as well as having been shown to directly 
correlate with AAA progression.(152)  
It has previously been demonstrated that patients with asymptomatic AAA exhibit a 
hypercoagulable and hypofibrinolytic state characterised by increased thrombin 
generation, activity and fibrin turnover.(83,153,154) It has further been hypothesised 
that this prothrombotic diathesis results from the release of biologically active 
moieties from the AAA wall and intra-luminal thrombus,
  
and this is supported by the 
observation that exclusion of the AAA following OR and EVAR leads to a 
normalisation of coagulation in most patients.(155,156)
 
In further work, serum IL-1α, 
IL-1β, Il-4, IL-6, IL-8, IL-10, interferon (IFN)-γ, MCP-1 and tumour necrosis factor 
(TNF)-α and TNF-β were measured before and 6-months after EVAR repair.(157)
 
IL-1β, IL-6, IL-10, IFN-γ, TNF-α and -β were detectable pre-operatively and did not 
significantly change after EVAR, but by contrast, serum IL-1α and IL-8 levels fell 
significantly by 6 months after EVAR although only IL-1α, but not IL-8, positively 
correlated with AAA size.(137) 
The methods through which IL-1α is measured however remains a bone of 
contention, as will be shown in greater detail as part of our own work in Chapter 7. A 
review of the literature identified that a variety of research groups, studying different 
pathologies, have shown a range of IL-1α titre values, raising the question whether is 
variability between manufacturers’ kits and also between batches of kits produced by 
the same company: 
 One study evaluated serum IL-1α in patients with ovarian epithelial cancer 
against healthy controls. Using an ELISA immunoassay (R&D Systems, 
Minneapolis, USA), they reported that of the 35 patients with disease, 30 had 
serum titres <50pg/ml and 5 between 100-500pg/ml, whilst in the control 
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group of 36 patients, 33 had titres <20pg/ml, and the remaining 3 titres 
between 50-200pg/ml.(158)  
 Another study, using the same immunoassay, studied serum IL-1α in 66 
patients with systemic sclerosis (SS) against 19 age- and sex-matched 
controls. It reported IL-1α titres in the SS group of mean 4.95±0.28pg/ml, and 
in the control group 4.52±0.29pg/ml, and differences were statistically 
significant.(159)  
 A further study using the same immunoassay compared serum IL-1α in 
patients with acute viral hepatitis to controls. It reported mean titres of 15 
±8.8pg/ml in those with the disease against 1.1±2.7 in the control group.(160)  
 Another study, using a different immunoassay (LINCOplex® Multiplex 
immunoassay, Linco Research Inc., MO, USA), evaluated serum IL-1α in 
patients with rheumatoid arthritis (RA) against age-matched controls. It 
reported mean IL-1α titres in 169 patients with the disease of 144pg/ml (range 
48-380), and in the 92 controls, mean titres of 97.8pg/ml (range 33-
398.4).(161) 
These show that there is a dynamic range of results in those with pathology between 
kits produced by one or different companies. The difficulty is however interpreting 
whether this is due to a ‘true’ difference in results, because of the disease process’ 
being studied, or if it due to variations between kits. The variability of results 
between the studies in their respective control groups is therefore of particular 
interest, as one would intuitively expect similar titre ranges, particularly in kits from 
the same manufacturer in ‘healthy’ control subjects. One possible reason for the 
differences across kits in this group may be that the age-range of the patients studied 
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Chapter 6: Results from an analysis of the natural history of AAA in 
our own patient population at HEFT 
Introduction 
The UK Small Aneurysm Trial (UKSAT) and the Veterans Affairs Aneurysm 
Detection and Management (ADAM) study have shown that the risk of rupture in 
asymptomatic AAA <55mm MAPD is approximately 1%/year and that routine 
surgical intervention in such patients confers no benefit.(36–38)
. 
For this reason, 
asymptomatic AAA <55mm in MAPD are usually entered into a US-based 
surveillance programme and subsequently offered intervention when the risks of 
rupture, based upon absolute AAA size and growth rate, are believed to exceed those 
of OR or EVAR. As would be expected, the interval gap between surveillance scans 
decreases the larger the AAA MAPD. UKSAT indicates that patients with AAA of 
<40, 41 to 45, and >45mm MAPD can safely be offered US at 24, 12 and 3-6 
monthly intervals.(36–38) However, more recent evidence suggests that these 
intervals can be safely increased to 3, 2 and 1-yearly for AAA of MAPD 30 to 39, 40 
to 44, and 45-54mm respectively thus significantly improving patient acceptability 
and the cost-effectiveness of AAA surveillance, whilst maintaining a <1% risk of 
AAA size exceeding 55mm between screening visits.(162–165)
 
In fact, the most 
recent Society of Vascular Surgery guidelines, published in 2009 and the American 
College of Cardiology/American Heart Association (ACC/AHA) 2005 guidelines on 
surveillance scans recommend US or CT-based surveillance every 6 to 12 months for 
aneurysms 40 to 54mm in diameter, and for AAA 30 to 40mm, suggest that imaging 
every two-to-three years is sufficient.(166,167) If such recommendations are 
internationally adopted, then this will have significant implications for screening 
42 
 
programmes, such as the UK National AAA Screening Programme (UK-NAAASP), 
where the surveillance intervals (annually for AAA measuring 30 to 44mm and 3-
monthly for those with MAPD between 45 to 54mm) are still based on the UK 
Multicentre Aneurysm Screening Study (MASS).(36–38) Given the conflicting data 
and recommendations in the literature, it is perhaps unsurprising that surveillance 
intervals vary considerable at international, national and regional levels.(163) At 
present our local HEFT surveillance protocol requires annual scans for AAA with 
MAPD ≤39mm, 6-monthly scans for AAA MAPD between 40 and 49mm, and 3-
monthly scans for AAA with MAPD between 50 and 55mm. Once the AAA exceeds 
50mm the patient is usually referred on to a vascular surgeon for further 
investigations pending a decision for intervention. The increased frequency of scans 
as the AAA enlarges is deemed reasonable on the grounds that US-imaging carries a 
relatively low-cost and reduces the potential risk of losing patients to follow-up from 
extended intervals between scans, as gaps in surveillance scans have been shown to 
be the factor most predictive of rupture in patients with known AAA.(168)  
Although forthcoming UK NICE national guidelines on AAA (including 
surveillance) will reduce non-evidence-based variability in practice and improve 
cost-effectiveness, it is important that clinical decision-making regarding AAA 
intervention takes into account potentially important individual patient factors such 
gender, smoking status, diabetes, blood pressure, hypercholesterolaemia, other co-
morbidity, and patient preferences.(169–171) 
Aims 
The aim of this study, therefore, was to examine factors affecting AAA growth in 




Retrospective interrogation of the prospectively gathered and maintained 
computerised HEFT AAA surveillance database was undertaken for the period 1
st
 
February 1993 to 31
st
 August 2013. All patients with AAA of MAPD ≥30mm and at 
least one follow-up scan were included. Those patients with AAA ≥55mm at first 
scan and those with only one measurement were excluded from analysis of growth 
rates. For the former it was due to the inherent selection bias of maintaining such 
patients in surveillance despite having reached threshold intervention MAPD, and for 
the latter because growth rates could not be calculated from isolated MAPD 
measurements. Those with MAPD <30mm at time of first scan were excluded from 
the analysis until such a time, if it occurred, as their aortic measurements were 
greater than 30mm, as prior to that they were not defined as having an AAA.  
Overall, 5363 AAA measurements were analysed (4906 US, 442 CT, and 15 MRI). 
The average duration of follow-up was 5 years 7 months with a mean (median; 
range) of 10 (9; 2 to 29) measurements per person. Patient demographics including 
co-morbidity, smoking status, use of BMT, death and cause of death were collected 
through review of HEFT electronic patient records (EPR) and other hospital 
databases. For each patient a MAPD growth rate was derived by dividing the change 
in MAPD between the first and last scans by the time elapsed between them. Growth 
rates were censored at MAPD of 55mm, as most patients went on to have OR or 
EVAR at this stage. Large negative (>0.5mm/month) and positive (>1.0mm/month) 
growth rates were excluded as they were believed to be spurious. The effect of 
patient factors on growth rates was analysed using independent sample t-tests and 
one-way ANOVA for comparisons of two, and more than two, groups respectively. 
A survival analysis was performed using the compound outcome of all-cause 
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mortality or OR/EVAR. Univariate analysis was performed using Kaplan-Meier 
survival curves, followed by a multivariable Cox regression model with a backwards 
stepwise entry method. All analyses were performed using IBM SPSS Statistics 22 
(IBM Corp. Armonk, NY), with p<0.05 deemed to be indicative of statistical 
significance.  Bonferroni or Šidák corrections were not made to adjust the p-values 
when performing multiple comparisons, so it is possible that some of the results 
obtained occurred simply through chance alone.  
Results 
Twenty patients with initial AAA MAPD >55mm, nine with only one scan, six with 
negative growth rates >0.5mm/month and two with positive growth rates 
>1mm/month were excluded leaving 692 patients. Of these, 575 (83.1%) were men 
of mean (range, [SD]) age 72 (45-89, [±6.7]) years at time of entry into the AAA 
surveillance programme for analysis. Mean (range, [SD]) MAPD at first and last 
scans was 37 (30-44 [SD±6]) and 40 (30-55, [±10]) mm respectively. There was no 
significant difference between men and women in starting AAA MAPD. Mean 
(median/range) AAA MAPD growth rate was 2.3 (1.9/0-13.1) mm/year overall; 
2.2mm/year for men and 2.7mm/year for women (p = 0.05, t-test) 
A further 73 patients were entered into surveillance despite having MAPD <30 
(range 15 to 29mm) and underwent 109 (106 US, 3 CT) scans. Four remained in 
surveillance for up to 10 years, undergoing a total of 18 US scans, but never reached 
MAPD ≥30mm before being discharged. Of the 69 patients whose AAA MAP 
progressed to >30mm, 10 went on to OR or EVAR. 
Co-morbidities, smoking status and BMT are shown in Table 1. Most patients (n = 
608, 87.9%) were ≥65
 
years at the time of entry into surveillance and had associated 
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cardiovascular risk factors such as hypertension (71.4%), IHD (44.7%) and a positive 
(ex-, or current) smoking history (66.9%). Additionally, most (83.8%) were 
maintained on some form of BMT.  
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Co-morbidity N Data missing 
BP 492 (71%) 24 (3.5%) 
IHD 309 (44.7%) 23 (3.3%) 
AF 100 (14.5%) 1 (0.1%) 
COPD 163 (23.6%) 25 (3.6%) 
DM 107 (15.5%) 25 (3.6%) 
Hypercholesterolaemia 170 (24.6%) 32 (4.6%) 
ESRF 89 (12.9%)  
CCF 77 (11.1%)  
Active history of cancer 138 (19.9%)  
Dementia 36 (5.2%)  
Smoking status  50 (7.2%) 
Never 165 (23.8%)  
Ex-smoker 290 (41.9%)  
Current 187 (27.0%)  
BMT  35 (5.1%) 
No BMT 77 (11.1%)  
Aspirin/Statin 445 (64.3%)  
Aspirin only 40 (5.8%)  
Statin only 56 (8.1%)  
Warfarin/Statin 22 (3.2%)  
Other combination 17 (2.5%)  
Table 1. Characteristics of the 692 patients in the historical database of HEFT 
AAA surveillance  
BP: hypertension; IHD: ischaemic heart disease; AF: atrial fibrillation; COPD: chronic obstructive 
pulmonary disease; DM: diabetes mellitus; ESRF: end-stage renal failure; CCF: congestive cardiac 
failure; BMT: best medical therapy 
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Elective AAA repair (57 OR, 82 EVAR) was undertaken in 139 (20.1%) patients at a 
mean (range, [SD]) age of 75 (54-87, [±6]) years and mean MAPD of 58mm. There 
were 124 men of mean age of 75 years and 15 women of mean age of 77 years. There 
was no significant difference between men and women in terms of MAPD at time of 
surgery (p = 0.914). Those who eventually underwent surgery grew on average at 
4mm/year while those that did not grew at 1.7mm/year (p<0.001, t-test).  
Death in surveillance 
Of the 692 patients, there were 213 (30.8%) deaths in 164 men of mean (range, [SD]) 
age 80 (61-94, [±6]) and 50 women of mean 81 (66-92, [±6]) years at time of death.. 
Of these, only 25 (11.7%) were AAA-related (Table 2). Of those who died, 171 
(80.3%) patients, 131 men of mean (range, [SD]) age 80 (61-94, [±7]) and 41 women 
of mean (range, [SD]) age 82 at time of death (66-92, [±6]) years died in surveillance 
having never been offered AAA surgery. A total of 133 (62.1%) deaths occurred in 
patients who never reached a MAPD >55mm. Of these, 102 were men of mean [SD] 
age 80 [±6] years and mean growth rate of 1.9mm/year.  
A further 38 patients died without having surgical AAA repair despite having MAPD 
≥55mm at time of death. Surgery in this group was precluded on the grounds of 
advanced age, significant cardiovascular co-morbidity and metastatic malignancy or 
patient refusal (n=1). Mean age at time of death in this group was 82 [±7] years. Of 
these, 34.2% (n=13) died of AAA rupture.  
A total of 42 patients died within the follow-up period having undergone AAA 
repair, 8 of whom were recorded as post-operative ‘in-hospital’ deaths (3 emergency 
OR, 2 elective OR, and 3 elective EVAR). Excluding the 8 post-operative deaths, 
26/34 of these patients were men, with mean age at time of surgery being 77 years. 
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Mean time to death was 49 [±28] months post-operatively, and mean age at death 
was 77 years [±5].   
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 All deaths 
(n = 214) 
Deaths 
(MAPD ⩽55mm 
at last scan) 
(n = 133) 
Deaths 
(MAPD > 55mm  at last scan 
and no AAA surgery) 
(n = 39) 
Deaths (after AAA 
repair) 
(n = 42) 
Unknown* 30 20 6 4 
Non-AAA-related 
Cardiac arrest 19 - - - 
IHD/MI 8 20 4 4 
Malignancy 53 36 7 9 
Pneumonia 32 21 2 10 
CVA 7 5 1 1 
Sepsis 11 9 1 1 
PE 3 2 - - 
ESRF 3 2 1 - 
COPD 9 6 1 1 
CCF 8 6 1 1 




5 - - 8 
Rupture (operated) 3 - - - 
Ruptured   (not 
operated) 
17 4 13 - 
                      Table 2. Cause of death in the 214 patients who died during HEFT AAA surveillance as recorded on death certification 
*Where cause of death is recorded as unknown the death certificate was unavailable and interrogation of individual patient records also 
yielded no obvious cause. 
HT: hypertension; IHD: ischaemic heart disease; MI: myocardial infarction; CVA: stroke; PE: pulmonary embolus; ESRF: end-stage 




Overall, only 27/692 (3.9%) patients went on to rupture. Of these, 11/27 (40.7%) 
ruptured with a last recorded MAPD <55mm. Of these, seven were men with mean 
AAA size at time of last scan 51mm (47-54, [±2]) and mean growth rate 2.7mm/year. 
Seven of these proceeded to emergency surgery, with two deaths in the immediate 
post-operative period. The mean time between last known surveillance scan and 
rupture date was 531 days. One patient had been lost to AAA surveillance follow-up 
prior to re-presenting with rupture 4 years later. At the time of her last surveillance 
scan, the AAA measured 47mm and she underwent successful emergency OR. 
Another patient had been discharged from AAA surveillance follow-up due to age 
(91 years) and co-morbidities and presented 3years later with a rupture but was not 
taken forward for emergency surgery. 
Of those 16 patients who ruptured with AAA >55mm, 11 were men with mean AAA 
size of 66mm at last scan  (55-120, [±15]) and mean AAA growth rate of 
6.1mm/year. This difference in growth rates between those who ruptured <55mm and 
those who ruptured at >55mm was statistically significant (p = 0.004 t-test).  
A total of ten patients underwent emergency surgery (6 OR, 4 EVAR) for ruptured 
AAA, of whom 3 died in hospital. Of the remaining 17, four did not survive to the 
operating theatre, and the remaining 13 were deemed unsuitable for emergency 
surgery on the grounds of advanced age, significant co-morbidity or because they 
refused surgery (n=1). Mean age in these 13 patients was 82 (67-94, [±8]) years and 




Comparing mean growth rates in those who ruptured (0.38 mm/year) and those who 
did not (0.18 mm/year), we found no significant difference in mean AAA growth rate 
(p = 0.838, t-test).  
Baseline AAA MAPD on entry into surveillance 
There was no statistically significant difference in baseline MAPD between men and 
women (p=0.687) (Table 3).  Younger patients had significantly smaller MAPD 
upon entry to the surveillance programme (p<0.001) Patients with a baseline MAPD 
>40mm were significantly more likely to be offered surgery (p<0.001). Specifically 
14.3% (n = 62) patients with AAA <40mm at point of entry into surveillance 
proceeded to undergo surgical repair whilst 34.4% (n = 87) of those with AAA 
between 40mm and 50mm at first surveillance scan went on to require surgical 
intervention. Those who went on to be offered elective AAA repair had 4mm larger 
MAPD at baseline than those who did  not (40mm vs. 36mm) (p<0.001). 
Additionally, those who went on to rupture had 4mm larger MAPD at baseline 





N First AAA (mm) p-Value 




95 35 (6) 
 65 - 69 
178 
36 (6) 
 70 - 74 








37 (6)  
Female 117 














37 (6)  
Yes 
25 41 (6)  
Table 3. Baseline AAA measurements of patients in HEFT AAA surveillance 
Data reported as: "mean (SD)", with p-values from t-tests, for comparisons of two 




AAA growth rates (mm/year) 
Mean growth rate for all 692 patients was 2.3mm/year (Table 4). Females were 
associated with significantly higher AAA growth rates compared to men (2.7 vs. 
2.2mm/year) (p=0.025). Analysis of co-morbidity revealed no significant differences 
except that those with diabetes had significantly lower growth rates (1.7 vs. 
2.5mm/year) (p=0.002). Additionally, although the result did not quite reach 
significance, active smokers also had higher AAA growth rates compared to those 
who were ex-smokers or those who had never smoked.  
Those who were subsequently offered intervention had significantly higher growth 
rates than those who were not (4.0 vs. 1.8mm/year) (p<0.001) and those with more 









Age at First Scan 
 
 0.350 
< 65 95 2.2 (2.1) 
 
65 - 69 178 2.1 (1.7) 
 
70 - 74 203 2.2 (1.8) 
 
75+ 216 2.5 (2.6) 
 
Sex   0.025* 
Male 575 2.2 (2.0)  
Female 117 2.7 (2.7)  
Death in surveillance 
 
 <0.001* 
No 478 2.1 (2.0) 
 
Yes 214 2.8 (2.4) 
 
Surgery   <0.001* 
No 543 1.8 (1.8)  




No 665 2.2 (2.0) 
 





No 360 2.4 (2.2) 
 





No 504 2.3 (2.1) 
 





No 560 2.5 (2.3) 
 





No 176 2.5 (2.3) 
 





Never 165 2.1 (2.1) 
 
Ex 290 2.2 (1.9) 
 





No 490 2.4 (2.3) 
 





None 77 2.4 (2.2) 
 




Aspirin only 40 2.0 (2.2) 
 
Statin only 56 2.0 (1.9) 
 
Warfarin & Statin 22 2.4 (2.3) 
 





No 603 2.3 (2.2) 
 





No 615 2.3 (2.1) 
 





No 591 2.3 (2.2) 
 
Yes 100 2.1 (2.1) 
 
Active/History of CA 
 
 0.881 
No 554 2.3 (2.2) 
 
Yes 138 2.3 (2.1) 
 
Table 4. Factors affecting AAA growth rates in the HEFT AAA surveillance 
database patient cohort 
Data reported as: "mean (SD)", with p-values from t-tests, for comparisons of two 




Kaplan-Meier estimated surgery-free survival 
Those patients who entered surveillance at a younger age with smaller, more slowly 
growing AAA were significantly more likely to be alive and free of AAA 
intervention at 5 and 10-years (Table 5). Of those aged > 75 years upon entry to 
surveillance, only 67.8% and 31.3% were alive without AAA-intervention at 5 and 
10-years. Of those who entered with a MAPD 44 to 49mm, 51.1% and 19.7% were 
alive without AAA-intervention at 5 and 10years. Significantly fewer women than 
men were alive without AAA-intervention at 5- (70.1 vs. 78.1% respectively) and 10-
years (28.2% vs. 44.1%). 
There was no relationship between a diagnosis of ischaemic heart disease (IHD), 
chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), 
hypertension, hypercholesterolaemia, congestive cardiac failure (CCF) or dementia 
and 5 or 10-year AAA intervention-free survival. Those with atrial fibrillation (AF) 
and end-stage renal failure (ESRF) were significantly more likely to die, or need 
intervention, than those who did not. Those who were active smokers also had 
significantly lower 5- and 10-year surgery-free survival rates than those who were 
ex-smokers, who in turn had lower rates than those who had never smoked. There 












Age at First Scan       <0.001* 
< 65 95 0.816 0.495   
65 - 69 178 0.824 0.530   
70 - 74 203 0.791 0.376   
75+ 216 0.678 0.313   
Initial AAA Size (mm)       <0.001* 
< 30 72 0.942 0.697   
30 - 44 518 0.801 0.419   
 44 - 49 80 0.511 0.197   
50+ 22 0.120 .   
AAA Gradient (mm/month)       <0.001* 
< 0.1 252 0.882 0.614   
0.1 - 0.2 223 0.846 0.482   
>0.2 217 0.558 0.116   
Sex       0.023* 
Male 575 0.781 0.441   
Female 117 0.701 0.282   
Rupture       <0.001* 
No 665 0.773 0.438   
Yes 27 0.640 0.080   
IHD       0.518 
No 360 0.738 0.444   
Yes 309 0.782 0.351   
COPD       0.553 
No 504 0.769 0.383   
Yes 163 0.726 0.423   
DM       0.354 
No 560 0.737 0.413   
Yes 107 0.868 0.302   
BP       0.165 
No 176 0.700 0.411   
Yes 492 0.780 0.389   
Smoking status       0.002* 
Never 165 0.884 0.484   
Ex 290 0.755 0.378   
Current 187 0.671 0.340   
Cholesterol       0.951 
No 490 0.744 0.415   
Yes 170 0.816 0.357   
BMT       0.806 
None 77 0.769 0.483   
Aspirin & Statin 445 0.761 0.398   
Aspirin only 40 0.711 0.309   
Statin only 56 0.789 0.417   
Warfarin & Statin 22 0.727 0.302   
Other 17 0.857 .   
ESRF       0.008* 
No 603 0.772 0.442   
Yes 89 0.741 0.285   
CCF       0.177 
No 615 0.769 0.425   
Yes 77 0.757 0.376   
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Table 5. Kaplan-Meier estimated surgery-free survival  
Data reported as Kaplan-Meier estimated survival, with p-values from log-rank tests. 
*Significant at p<0.05 (bold)  
AF       0.030* 
No 591 0.771 0.439   
Yes 100 0.749 0.315   
Active/History of CA       0.006* 
No 554 0.773 0.450   
Yes 138 0.745 0.296   
Dementia       0.954 
No 656 0.772 0.417   
Yes 36 0.69 0.434   
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Cox-regression multivariable analysis 
A further multivariable survival analysis looking at survival to death or surgery was 
then performed using all the covariates identified in the Kaplan-Meier analysis to 
look at patient survival related to AAA surgery, or death (Table 6). Analysis was 
performed to determine whether any factors could be used to predict a future need for 
AAA surgical intervention or patient death. As expected, patients with larger AAA at 
point of entry into surveillance were significantly more likely to undergo intervention 
(p < 0.001). The same applied to those who were older (p = 0.005). Interestingly, 
AAA growth rate (mm/month) was also a significant predictor for surgical 
intervention, with a hazard ratio of 1.57 for patients with an AAA growth rate of 0.1 
– 0.2 mm/month (p = 0.007) and 4.21 if the growth rate was >0.2 mm/month (p < 
0.001), relative to those with a growth rate of <0.1 mm/month. Additionally, those 
who continued to smoke were also more likely to undergo intervention when 
compared to those who had never smoked (HR=1.97, p<0.001). Interestingly, even in 
those who claimed to have stopped smoking, the risk of intervention remained 
significantly increased (p<0.001), with a hazard ratio of 1.78 relative to those who 
had never smoked. Those with a history of AF or a known diagnosis of malignancy 
were also more likely to undergo intervention, or die in surveillance. The effect of 
COPD did not reach statistical significance after accounting for the other factors in 
the model (HR 0.79, p=0.086).  
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  Hazard Ratio (95% CI) p-Value 
Age at First Scan   0.005* 
< 65 - - 
65 - 69 0.75 (0.49 - 1.14) 0.182 
70 - 74 1.09 (0.72 - 1.64) 0.682 
75+ 1.35 (0.90 - 2.03) 0.146 
Initial AAA Size (mm)   <0.001* 
< 30 - - 
30 - 44 2.46 (1.52 - 3.97) <0.001* 
44 - 49 6.92 (3.89 - 12.32) <0.001* 
50+ 23.22 (11.60 - 46.49) <0.001* 
AAA Gradient (mm/month)   <0.001* 
< 0.1 - - 
0.1 - 0.2 1.57 (1.13 - 2.17) 0.007* 
>0.2 4.21 (3.10 - 5.71) <0.001* 
COPD   0.086 
No - - 
Yes 0.79 (0.60 - 1.03) 0.086 
Smoking status   <0.001* 
Never - - 
Ex 1.78 (1.31 - 2.43) <0.001* 
Current 1.97 (1.41 - 2.75) <0.001* 
AF   0.004* 
No - - 
Yes 1.53 (1.14 - 2.05) 0.004* 
Active/History of CA   0.007* 
No - - 
Yes 
1.46 (1.11 - 1.93) 0.007* 
Table 6. Cox-regression multivariable analysis 
Results from a backwards Cox regression model, with all of the variables in the 
Kaplan-Meier estimated survival analysis considered for inclusion. COPD = chronic 
obstructive pulmonary disease; AF = atrial fibrillation; CA = cancer; CI: confidence 




Limitations of study 
The presented analysis is a comprehensive description of the natural history of AAA 
in our local HEFT AAA patient population between February 1993 and August 2013. 
However, the dataset failed to capture those patients who had moved away from our 
patient catchment area during surveillance, or who were lost to follow-up for 
whatever reason. Additionally, as data was sourced from EPR, it was not possible to 
account for when, during the course of their surveillance, the variables used in the 
analysis (e.g.: co-morbidity and smoking status) could be defined. For example, 
patients may not have been diagnosed as diabetic at the time of entering the 
surveillance programme, but may have gone on to develop diabetes at a later date. 
The data entry did not account for this; they were simply recorded as being diabetic, 
as if they had been so for the full duration of surveillance. Likewise, they may have 
been commenced on BMT at any time during surveillance, but our analysis did not 
differentiate between a difference in e.g. AAA growth rates before or after BMT 
initiation; it simply recorded them as being on said medication as if they had been on 
it for the duration of their time in surveillance.  
Discussion 
This study has provided much useful information regarding the natural history of 
AAA in our local HEFT patient population, which can hopefully be used to progress 
the future delivery of surveillance services in our Trust.  The analysis covers a twenty 
year period, and excluding those who were lost to follow-up or who left our patient 
catchment area during the course of this period, provides exhaustive data on all 
patients with AAA.  It is our belief that the AAA surveillance programme at HEFT is 
probably not greatly different to those found at other NHS Trusts managing AAA 
patients, and so our results are generalisable. Historically surveillance scans at HEFT 
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were performed by local radiological departments, but with the advent of trained 
(vascular) clinical nurse specialists (CNSs) and improvements in US/employment of 
dedicated vascular-trained US-technicians, there has been a shift towards CNS-led 
surveillance clinics. This has greatly eased the burden on stretched radiology services 
and vascular surgeon out-patient consultant clinics, as patients can now have their 
AAA monitored in a separate setting.  
The main finding of this study is that, over a 20-year period, a huge number of scans 
are performed for AAA surveillance, a significant proportion of which are on patients 
who are kept in the surveillance programme inappropriately. Our results report 73 
patients being entered into surveillance and undergoing 109 scans despite not 
actually having AAA. This represents an inappropriate use of increasingly scarce 
healthcare resources. Although it is impossible to retrospectively calculate the 
individual financial burden this will have placed on HEFT in terms of staffing and 
costs, a simple calculation at today’s current national tariff of £43 per US (for an US 
which takes less than 20 minutes, as most surveillance scans do) including reporting 
fees, (taken from the 2016/17 National Tariff Payment system report from produced 
by Monitor and NHS England) yields a figure of £4558 wasted performing these 109 
US scans alone. Additional to the financial cost to HEFT is the unquantifiable 
financial, social and emotional cost to the patients involved, in particular for the four 
patients who remained under US-surveillance for up to a decade without ever 
reaching aortic diameters definable as aneurysmal. 
That only 20% of patients entered into the surveillance programme underwent 
elective surgery also raises interesting questions about the frequency of screening 
intervals and what such rigorous surveillance achieves. Less than 4% of patients 
experienced rupture, of whom 41% had AAA which ruptured at MAPD less than 
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55mm at time of last scan and of all the ruptured cases, less than half (37%) 
proceeded to emergency repair.  
Interestingly, of the many patient-related factors investigated, none were significantly 
correlated with rupture risk. This highlights the need to look elsewhere; specifically 
at AAA-specific factors such as biological markers within patients which may relate 
to aneurysm ‘activity’ or growth and rupture rates.  
Our results identified that those with growth rates >4.6mm/year were significantly 
more likely to rupture. However identifying such patients in a large, busy unit such 
as ours requires close, individual monitoring of individual growth patterns, which is 
unlikely to be sustainable or feasible. Additionally, it raises the question that even if 
such patients were identified, what to do with them?  There is no existing Level 1 
evidence to compel us to offer early intervention in patients with rapidly expanding 
AAA, and until such a point where there is, simply identifying patients at increased 
risk does not necessarily confer patient-benefit. One could argue that at least in 
identifying such patients, they could be offered more regular imaging to monitor 
growth, but perhaps the bigger issue here is to say that size alone is not a sufficiently 
accurate marker of AAA-associated mortality risk. Arguably the decision to perform 
elective OR or EVAR should not be based on AAA MAPD as the absolute factor, but 
should also take into account individual patient-related factors such as expansion 
rates. Our results show that patient-related factors have little role in identifying ‘at-
risk’ sub-groups who are more likely to succumb form AAA rupture.  
Our results corroborate previously published work in that they suggest that female 
gender and smoking are associated with significantly faster AAA expansion and that 
DM appears to have a ‘protective’ role, in that it slows AAA expansion. Results from 
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other studies have shown that women experience a higher rate of AAA rupture when 
compared to men with the same AAA MAPD.(172)  
Few published papers comment on the non-AAA related causes of death in patients 
with AAA, whilst ours clearly show that most patients who die in surveillance do so 
of non-AAA-related causes, most commonly malignancy.  
Conclusions 
Analysis of the HEFT AAA surveillance database has highlighted areas for service 
improvement. Specifically, it is important not commence surveillance in patients who 
are very unlikely to ever grow to a point where AAA surgery would be contemplated 
on grounds or age and/or co-morbidity.  Similarly, patients need to be discharged 




Chapter 7: Results of a failed run of serum IL-1α analysis and 
the subsequent methodology study from which later studies 
were derived 
In a pilot study we previously demonstrated that some patients with AAA have 
elevated serum IL-1α levels and that EC activation in vitro in response to serum from 
these patients, can be blocked by anti-IL-1α antibodies.(137) For these reasons, we 
postulated that IL-1α may represent a clinically useful biomarker of AAA 
progression and response to treatment. In order to further investigate this hypothesis, 
we anticipated undertaking a large prospective cohort study examining the 
relationship between serum IL-1α and various AAA- and patient-related variables.  
A number of commercially available assays are available to measure serum IL-1α 
levels in humans. The majority work on standard sandwich enzyme-linked 
immunosorbent (ELISA) principles, involving a micro-titre plate pre-coated with a 
monoclonal anti-IL-1α specific antibody. Following addition of antigen-containing 
serum, a biotinylated polyclonal antibody specific to IL-1α is then added to complete 
the ‘sandwich’. An avidin-conjugated complex, which has a high binding affinity to 
biotinylated products, allows signal amplification prior to addition of an organic 
enzyme substrate that reacts with the conjugated complex to induce a colour change. 
This can then be quantified using chromogenic techniques.  
An alternative to the micro-titre plate based immunoassays is the bead-based 
multiplex system, which works on the same principles described above, but utilises 
magnetic microspheres (‘beads’) pre-coated with the capture antibody instead of the 
solid surface of the plate and streptavidin-phycoerythrin (SA-PE) as the final 




The previous, published pilot study undertaken by other members of our research 
group was performed on serum samples collected and immunoanalysis performed by 
the Clinical Immunology Service (CIS) at the University of Birmingham using their 
standard IL-1α measuring platform, a Bio-Rad Bio-Plex Pro commercially available 
immunoassay. With that in mind, we therefore embarked on collecting serum 
samples from patients with AAA as they attended our surveillance clinics at HEFT. 
In order to maximise the volume of patients recruited, we collaborated with vascular 
surgical colleagues at City Hospital, part of Sandwell and West Birmingham 
Hospitals NHS Trust (SWBH) with a plan to run the first cohort batch analysis once 
n = 100 patients had been recruited. As this was a large cohort of patients, in the 
interests of serum processing standardisation and to reduce the risk of technical error 
in a larger study, conducted over a long period of time, we utilised the services of a 
local bio-bank, the Human Biomaterials Resource Centre (HBRC), based at the 
University of Birmingham to process the whole blood samples. 
Once 96 patients had been recruited, and samples processed, an initial batch run was 
performed using a Bio-Rad immunoanalysis kit (‘Bio-Rad kit #1’). Surprisingly, 
results from this immunoanalysis yielded a completely negative set of results, with 
all 96 sample titres reported as below the detectable range of the ELISA assay. The 
standard curve readings, prepared by performing serial dilutions of one known 
standard concentrate of IL-1α as provided by the manufacturer prior to generating a 
standard curve using linear regression models as directed, demonstrated a ‘good fit’ 
meaning the kits worked appropriately (Figure 3). In light of this finding, we went 
back to the original paper to check for differences within the methodology. We found 
that in the original pilot study, the immunoanalysis kit used was manufactured by 
67 
 
Millipore and assays were measured on their Milliplex MAP immunoassay 
(Millipore, Billerica, Mass.), which is a bead-based multiplex system. Additionally, 
as the pilot study had used only a small number (n = 17) patients, serum processing 
of whole blood had been performed ‘in-house’ within the facilities of HEFT’s 
vascular research laboratories by the chief researcher, and slight differences in serum 
processing existed. In the 2011 study, samples were collected and immediately 
centrifuged at RT at 12K RPM for 10 minutes in serum separating tubes (SST) prior 
to aliquoting and storage at -80C. In using HBRC however, samples were collected at 
the end of clinics and transferred on ice, with a possible delay of no greater than six 
hours, before centrifugation and storage. Standard HBRC operating procedures were 
then followed for obtaining serum from whole blood (centrifugation at room 
temperature for 10 minutes at 4600RPM). In light of the literature suggesting that IL-
1α in serum is relatively stable when collected in commercial tubes and stored at 4C, 
it was not thought prior to the first run of assays that samples collected using the 
HBRC protocol would adversely affect results.(173) 
Thinking that the differences in titre values seen between the original pilot study and 
Bio-Rad kit #1 were attributable, for the most part, to the different immunoassay 
manufacturers’ kits, a subsequent re-run was performed using another Bio-Rad 
immunoassay (‘Bio-Rad kit #2’) and a Millipore immunoassay at CIS.  
This was performed on 41 of the samples tested on Bio-Rad kit #1 and 43 samples 
from the original 2011 study (‘Original 2011 Study’) from our research group which 
had detected positive IL-1α titres in serum samples of patients with AAA.(137) 
These samples had been stored since collection at -80C, but had been through an 
undetermined number of freeze/thaw cycles. Results from this were disappointing, 
with mostly negative results from this re-run (Table 7), showing inconsistent results 
68 
 
between the same samples run between the two kits, and that samples that were 
positive in both yielded markedly different values. Again, the standard curve 
readings from the kits suggested that they worked appropriately (Figures 4 and 5). 
The standard curve from the original 2011 study was not available, but one can only 
assume that the researchers at the time had checked its suitability. We also found that 
IL-1α titre values from the original study were much reduced when compared to their 
original 2011 values, although this may in part have been due to degradation of IL-1α 
as a result of prolonged storage at -80C. Discussion with the manufacturer Bio-Rad 
subsequently confirmed that there had been a change in the production of the kits, 
and that a different antibody was being used, however we were unable to identify the 
exact nature of the change. A methodology study to validate the collection, storage 
and processing of samples and to evaluate potential variability between different nine 
commercially available IL-1α immunoassays was then performed on a small (n = 10) 











Figure 3. Standard curve readings and graph from the first immunoassay run 
using Bio-Rad Kit#1 












































Sample Bio-Rad Kit #2 
HBRC samples 
(pg/ml) 



















1 UND UND 0.6 11.22 40.84872 
2 UND UND 0.91 UND 77.999 
3 UND UND 0.91 46.04 60.44681 
4 UND UND 2.19 37.11 109.5758 
5 UND UND 3.49 59.36 164.874 
6 UND UND 6.48 7.15 77.999 
7 UND UND 8.16 7.15 60.44681 
8 UND UND 11.56 1.87 77.999 
9 UND UND UND 1.23 138.2029 
10 UND UND UND UND 40.84872 
11 UND 8.29 UND 3.49 109.5758 
12 UND 127.75 UND 16.03 60.44681 
13 UND UND UND UND 60.44681 
14 UND UND UND UND 40.84872 
15 UND UND UND 6.48 40.84872 
16 UND UND UND 4.48 40.84872 
17 UND UND UND UND 124.1792 
18 UND UND UND 85.2 77.999 
19 UND UND UND 6.14 60.44681 
20 UND UND UND 1.23 40.84872 
21 UND UND UND UND 77.999 
22 UND UND UND UND 60.44681 
23 UND UND UND 52.15 77.999 
24 UND UND UND UND 40.84872 
25 UND UND UND 15.69 77.999 
26 UND UND UND UND 77.999 
27 UND UND UND UND 60.44681 
28 UND UND UND 0.3 40.84872 
29 UND UND UND 1.87 94.25367 
30 UND UND UND 6.81 77.999 
31 UND UND UND 5.48 40.84872 
32 UND UND UND 7.82 151.7441 
33 UND UND UND UND 40.84872 
34 UND UND UND 6.81 77.999 
35 UND UND UND 4.15 109.5758 
36 UND UND UND 7.15 77.999 
37 UND UND UND 0.91 124.1792 
38 UND UND UND 12.59 40.84872 
39 UND UND UND 74.61 111.9797 
40 UND UND UND 55.75 98.2595 
41 UND UND UND 66.61 56.30869 
42  UND  10.88 139.1327 
43  UND  28.61 56.30869 
Table 7. IL-1α titres for immune-analysis using two kits, with HBRC and 
original 2011 study samples. <UND = levels too low to be quantifiable  




Figure 4. Standard curve for Bio-Rad kit #2 
 
 















































































Before embarking on our larger study, we wished to establish that we could measure 
IL-1α in the serum of patients with AAA in a practical, reliable and reproducible 
manner. The aim of this next study, therefore, was to investigate the effect of two 
different serum processing methodologies and nine different (7 ELISA and 2 bead-
based) commercial immunoassays on serum IL-1α levels in patients with AAA. We 
simultaneously compared recombinant IL-1α (both 33kDa (Cal +ve) and 17kDa (Cal 
-ve) and to the best of our knowledge, are the first group to do so. 
Patient recruitment and sample collection and preparation 
Ten patients with asymptomatic AAA were recruited from the vascular out-patient 
clinics at HEFT. All were male, with mean age 70 years (range 64-83). Patient 
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(mm) 





























No No No No No No No No 






Yes Yes No No No No CABG 2008 






Yes Yes No No No No AF  




Yes No Yes No No No No Hypothyroidism 




No No No No No No No No 




Yes No No No No No No Hypothyroidism 




Yes No No No No No No No 
8 59 TAA Ex 
 
Yes Yes Yes Yes No No No 5/12 post OR 
with bilateral 
renal bypass 
9 100 TAA Ex 
 
Yes Yes Yes No No No No TB 
OR 1999 




Yes Yes Yes No No No No No 
Table 8. Patient demographics of the ten patient recruits for the IL-1α immunoassay methodology study 
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Following skin preparation with an alcohol-based antiseptic, whole blood was drawn 
from an antecubital fossa vein using a tourniquet, Vacuette® Multi-Sample Blood 
Collection Needles (21G-green) and Vacuette® Standard Tube Holders into multiple 
Vacuette® Z Serum Clot Activator tubes (Greiner Bio-One, Kremsmünster, Austria). 
In accordance with manufacturer’s guidelines, collection tubes were inverted 8 times 
to allow mixing and the whole blood permitted to clot at RT over 30 minutes. 
Two sample processing methodologies were then undertaken, one involving 
immediate, and the other delayed centrifugation. 
 Method A comprised immediate centrifugation of clotted whole blood (10 
min, 4600 RPM, RT) followed by aliquoting of serum into cryovials which 
were then transported on ice to the Human Biomaterials Resource Centre 
(HBRC) at the University of Birmingham where they were stored at -80C (all 
completed within 6 hours of specimen collection). 
 Method B comprised transfer of clotted whole blood on ice to the HBRC 
followed by centrifugation (10 min, 4600 RPM, RT), and then aliquoting of 
serum into cryovials for storage at -80C (all completed within 6 hours). 
Sufficient volumes of serum were placed in at least 9 cryovials to ensure that no 
samples were subjected to freeze/thaw cycles during immunoanalysis. 
Upon receipt, the nine immunoassays (Table 9) were stored in accordance with the 
manufacturers’ instructions. 
Immunoanalysis was performed on all of the kits, on consecutive days, within 6-




Manufacturer Name Cat no. Batch/Lot no. 
Cusabio Human Interleukin 1α (IL-1α) 
ELISA Kit 
CSB-E04620h I14153067 
BioLegend Legend Max™ Human IL-1α 434907 B154870 
Biosensis Human Interleukin 1 alpha Kit BEK-2033-1P BA01-30-2033 TK141212 
BioVendor Human Interleukin-1 alpha ELISA RBMS243/2R X12-170 
Thermo Scientific Human IL-1α ELISA Kit EH21LA NJ175968 
Boster Human IL-1α ELISA Kit EK0389 111871104 
RayBiotech Human IL-1α ELISA Kit ELH-IL1alpha-001 1228120199 
Millipore MILLIPLEX
®
 MAP Kit HCYTOMAG-60K-01 2115942 
Bio-Rad Bio-Plex Pro™ Assay for IL-1α 171-304070 310011908 
Table 9. Commercially available IL-1α kits tested in methodology study 
76 
 
All assays were run as per the manufacturers’ protocols provided, and optical density 
(OD) was measured using plate spectrophotometry at 450nm. Wavelength correction 
was performed when specified by individual manufacturers. 
Microplates were loaded with manufacturers’ standards as provided, undiluted serum 
samples (in triplicate) and known positive rIL-1α controls, cellular 33kDa and 17kDa 
subunits [calpeptin positive (Cal +ve) and calpeptin negative (Cal -ve) 
respectively].
**1 
ELISA endpoint absorbance was measured on a BioTek Synergy
®
 multi-detection 
microplate reader utilising KC4
®
 v3.4 software. Loading of the ELISA plates is 
shown in Figure 6. 
  
                                                          
**1
 rIL-1α, Cal+ve and Cal-ve controls were generously provided by Dr Murray 
Clarke, Division of Cardiovascular Medicine, University of Cambridge, 
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Bead-based assays were analysed using the Luminex(r) 100 system (Luminex Corp, 
USA) with Bio-Plex Manager 6.0 software (Bio-Rad, UK). 
IL-1α titres were calculated against standard curves generated from each assay using 
reference concentrations supplied by manufacturers. OD readings were converted to 
units (pg/ml) with GraphPad PRISM v5.0. 
In cases where bioassay results for the r-IL1α, Cal + ve or Cal - ve controls were out 
of an assay’s detectable range (UND), dilution studies were not subsequently 
performed to obtain quantifiable titre values as the purpose of running the controls 
was simply to verify that the immunoassays could detect IL-1α and both the 33kDa 
and 17kDa subunits. 
Results 
Ten male patients of mean (range, [standard deviation (SD)] age 70 (64-83, [±6.8]) 
years with asymptomatic, infra-renal AAA or Crawford extent 2 thoracoabdominal 
aortic aneurysms (TAA) (n=2) were studied. Mean AAA size as recorded on the day 
of serum sampling by US was 65mm (range 32 to 100mm [±22]). Patient 
















Other co-morbidity of 
note 
1 44 Infra-renal AAA 
No 
 
No No No No No No No No 





Yes Yes No No No No CABG 2008 





Yes Yes No No No No AF 
4 32 Infra-renal AAA 
Ex 
 
Yes No Yes No No No No Hypothyroidism 
5 32 Infra-renal AAA 
Ex 
 
No No No No No No No No 
6 48 Infra-renal AAA 
Yes 
 
Yes No No No No No No Hypothyroidism 
7 50 Infra-renal AAA 
Ex 
 
Yes No No No No No No No 
8 59 TAA 
Ex 
 
Yes Yes Yes Yes No No No 
5/12 post OR with 
bilateral renal bypass 
9 100 TAA 
Ex 
 
Yes Yes Yes No No No No 
TB 
OR 1999 
10 68 Infra-renal AAA 
Ex 
 
Yes Yes Yes No No No No No 
Table 10. Demographics of the ten patients recruited for the immunoassay methodology study 
HT: hypertension; IHD: ischaemic heart disease; CABG: coronary artery bypass graft; CCF: congestive cardiac failure; AF: atrial 
fibrillation; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; OR: open aneurysm repair; TB: tuberculosis; BMT: best 
medical therapy; TAA: thoracoabdominal aneurysm (Crawford extent 2)
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Serum IL-1α titres (pg/ml) using Method A and B on each immunoassay are shown 
in Table 11. Results of rIL-1α, Cal + ve and Cal - ve controls, including dilutions, 
are shown in Table 12. IL-1α titre results comparing Method A to Method B are 
shown in Figures 7 and 8.  
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 Table 11. IL-1α titres (pg/ml) for each of the 10 patient serum samples processed using Method A (immediate centrifugation and 
processing) or Method B (delayed centrifugation and processing using a regional biobank) on each of the immunoassays tested 
UND=levels below manufacturer’s detectable range.  





1A UND UND 9.7 UND UND UND UND UND UND 
1B UND UND 2.1 UND UND 1.0 0.65 UND UND 
2A UND UND 18.2 UND UND 67.8 UND UND UND 
2B 64.9 UND 24.0 UND UND 79.3 0.41 UND UND 
3A UND UND 17.1 UND UND 17.5 0 UND UND 
3B 28.4 UND 20.4 UND UND 30.7 UND UND UND 
4A UND UND UND UND UND 105.0 UND UND UND 
4B 114.4 UND 0.7 UND UND 116.4 UND UND UND 
5A UND UND UND UND UND UND UND UND UND 
5B 33.6 UND UND UND UND 4.9 UND UND UND 
6A UND UND 5.9 UND 40.1 0.9 0 UND UND 
6B 31.4 UND 8.0 UND UND 1.4 UND UND UND 
7A UND 23.0 27.0 UND UND 59.5 0 UND UND 
7B 68.2 2.0 27.4 UND UND 33.2 UND UND UND 
8A UND 3.8 UND UND UND UND UND UND UND 
8B 27.4 UND UND 0.9 UND 1.3 UND UND UND 
9A UND 7.8 7.6 UND 5.4 11.5 UND UND UND 
9B UND UND 8.3 UND UND 20.0 UND UND UND 
10A UND 12.8 27.7 2.3 UND UND 0 UND UND 
10B UND 6.7 23.7 2.5 UND 1.0 0 UND UND 
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Table 12. IL-1α titres (pg/ml) of positive rIL-1α (rIL-1α) controls and calpeptin-positive (Cal + ve) 33kDa IL-1α and calpeptin-
negative (Cal - ve) 17kDa IL-1α subunits 
OOR= levels above manufacturer’s detectable range, 
‘-’ = concentration of rIL-1α not tested at this concentration 





Cal +ve  0 OOR OOR OOR OOR 1163.2pg/ml 2.3pg/ml 1443.1pg/ml 1091.7pg/ml 




         
500ng/ml - - OOR OOR OOR - 3.9pg/ml - - 
250ng/ml - - - - 
- 
 
- 3.8pg/ml - - 




- OOR 146.5(pg/ml) OOR OOR - 1499.6pg/ml 1214.7pg/ml 
50ng/ml 0 - 179.7pg/ml 100.7pg/ml 458.6pg/ml 1315.8pg/ml - 745.9pg/ml 596.6pg/ml 
25ng/ml 0 - - - - - - - - 
5ng/ml - OOR - - - - - - - 






















Figure 7. Box plot comparing mean IL-1α titre concentrations obtained across 
all immunoassays using Method A (immediate processing) and Method B 






































Our study has compared two methods of whole blood processing using nine 
commercially available immunoassays for the detection and quantification of IL-1α 
in the serum of patients with AAA. Our aim was to identify a reliable and 
reproducible means by which to measure IL-1α ahead of a large cohort study 
investigating IL-1α as a biomarker of AAA progression and response to treatment.  
Our results show that although differences in serum processing techniques can affect 
results, the impact is not uniform and appears to be dependent on the immunoassay 
used. For example, Cusabio’s immunoassay was unable to quantifiably detect IL-1α 
in serum processed using Method A, but reported high titre results in seven samples 
processed using Method B. Possible explanations for why immediate processing 
(Method A) may result in low titres compared to delayed centrifugation (Method B) 
include sustained cellular release, or production, of IL-1α after blood has been drawn 
due to progressive, or continued, cell lysis.(174,175)  
In complete contrast however, ThermoSci’s immunoassay was able to quantify IL-1α 
in four samples processed using Method A, but none processed using Method B. 
Explanations for delayed serum processing methods resulting in low titres include the 
possibility of IL-1α degradation in the time taken for processing and storage. There is 
some evidence to suggest that IL-1α remains relatively stable, when stored at 4°C, 
for up to 24 hours, however environmental interactions or artefact effects within 
whole blood during processing may affect titre levels, or render detectable 





However, on aggregate, we found that there appears to be no real difference in mean 
IL-1α titre concentrations obtained across all immunoassays using either processing 
Method A or Method B. From this we have concluded that it is safe and feasible for 
researchers analysing IL-1α to utilise regional biobanks for sample processing and 
storage.  
One of the most striking findings in our results was the variability of results seen 
between samples from individual patients across the different immunoassays. 
Explanations for these findings include a lack of routine disclosure of the exact 
components of immunoassays by manufacturers, specifically the morphology of 
standards supplied, antibodies used and their corresponding epitope binding sites. 
Differences in these may affect an individual immunoassay’s ability to detect IL-1α, 
with falsely elevated, or low concentrations, due to non-specific binding.(176–179)  
Additionally, individual manufacturers may use different recombinant antibodies to 
produce each of their kits, which may cause incongruous results between assays or 
even inter-batch variation across assays from one manufacturer. This lack of 
concordance can pose problems to researchers, who may find that different kits 
produce markedly varied results.(176) 
Although there is a paucity of studies in the literature specifically looking at IL-1α, 
studies have shown that cross-technology comparisons are difficult. Significant 
differences in results have been found when measuring IL-1β using ELISA 
immunoassays and explanations for this include physical differences in binding sites 





Candidate markers may well be present in samples, but differences in detection or 
capture antibodies may result in failure due to incompatible binding sites or 
undetermined competitive antigen binding from other components in patient 
serum.(182) Additionally, endogenous proteases may fragment precursors in ways 
which render them undetectable.(178–181,183,184) 
The presence of auto-antibodies within serum samples causing interference within 
assays is a recognised flaw in immune-analysis and can lead to misleading results. It 
is as yet unknown whether such potential competitor auto-antibodies exist in the 
context of IL-1α assay binding sites, and there are no published studies investigating 
whether this is the case in the literature.  
In the case of IL-1α, which has multiple isoforms capable of exerting biological 
effects, the ability of an immunoassay to detect both pro- and mature-IL-1α is 
important as it is not yet known whether one, or both, have a role in AAA.(131,185) 
Our results show that, with the exception of the Cusabio immunoassay, all of the kits 
were able to detect IL-1α as well as both Cal +ve and Cal -ve isoforms. Possible 
explanations for the anomalous Cusabio results include differences in the structure or 
pharmacokinetics of these non-endogenous proteins which render them undetectable 
by the immunoassay, or which prevent epitope binding.(186,187) Technical 
malfunction is of course another possibility, either as a result of operator error or due 
to components within the individual assays failing to work correctly, perhaps as a 
result of product degradation during shipment and delivery.  
Our results identify and highlight a potentially serious problem for basic scientists 
embarking on studies such as ours. It is unlikely that the variability in results 




correctly, yet we have shown that a variety of manufacturers sell (expensive) kits 
which may, or may not, be able to accurately measure the moiety they claim to be 
able to quantify. The wider consequences of this appear to be profound; it is probable 
that there may be research groups investigating a variety of molecules in various 
pathologies who are largely unaware that the assays they are buying (at great 
expense) can produce such varied results. The implications of this are that this leads 
to (false) ‘positive’ data which can subsequently mislead researchers, or generates 
(false) ‘negative’ data which effectively stops further research in a field where had 
other immunoanalysis kits been used, could have resulted in positive biological 
results. 
Conclusions 
Our results demonstrate marked variability in IL-1α titre concentrations when using 
different serum processing techniques and between IL-1α immunoassays produced 
by different manufacturers. They suggest that researchers should be cautious when 
interpreting published data as absolute concentrations of IL-1α from different 
vendors are not interchangeable and differences in methodologies can impact results 
considerably. This may result in misleading conclusions being drawn about 
fundamental biological processes underpinning a wide range of inflammatory 
diseases.  
Our study suggests that conclusions of IL-1α’s role in pathological processes should 





Chapter 8: Study 1 looking at serum IL-1α titres in patients with 
asymptomatic, infra-renal AAA size, morphology and growth rates 
Infra-renal abdominal aortic aneurysms (AAA) are usually asymptomatic until 
complications arise, most commonly rupture. AAA size, and in particular MAPD, 
together with growth rates, are widely believed to be the best current predictors of 
rupture and so are the variables most often used in clinical practice to select patients 
for open surgical (OR) or endovascular aneurysm repair (EVAR).(36,37,42,43) 
AAA is widely recognised to be a chronic inflammatory condition that is separate 
from, but which often co-exists with, atherosclerosis due to shared risk factors.(188) 
Previous work from our and other groups has shown patients with AAA to have 
abnormalities in serum markers of inflammation and coagulation associated with a 
pro-thrombotic, pro-inflammatory, hypercoagulable diathesis.(79–82) However, it 
remains unclear whether AAA development and progression is primarily a result of 
biomechanical (blood pressure, AAA size and shape, shear and stress forces) or 
biological (disintegration of the aortic wall due to inflammation and disordered tissue 
re-modelling) factors, or both. 
An AAA intervention strategy based on size alone may leave patients with small 
(generally regarded as <55mm in MAPD) but nevertheless ‘biologically active’ AAA 
unprotected from rupture, whereas patients with large but biologically ‘quiescent’ 
AAA may be offered and possibly even harmed by unnecessary surgery. There is, 
therefore, an urgent need to identify better predictors of rupture so that the available 
health care resources can be used in the safest and most clinically and cost-effective 
manner. One particular field of current interest is identification of reliable clinical 




Interleukin-1 alpha (IL-1α) is a pro-inflammatory cytokine that is not normally 
detectable in the circulation in health.(127) IL-1α has been linked with 
cardiovascular disease in general and it is known that some patients with aortic 
disease have detectable IL-1α titres.(142,134,103,89,94) In a pilot study, we 
demonstrated that patients with AAA had detectable serum IL-1α levels which 
appeared to be related to AAA diameter. Additionally, we found that EC activation in 
vitro in response to serum from these AAA patients was blocked by anti-IL-1α 
antibodies.(137) 
Aims  
In a pilot study, we reported a relationship between abdominal aortic aneurysm 
(AAA) diameter and serum interleukin (IL)-1α levels and that EC activation in vitro 
in response to serum from AAA patients was blocked by anti-IL-1α antibodies. We 
now aim to further investigate the relationship between serum IL-1α and 
asymptomatic infra-renal AAA size, morphology and growth rates.  
Methods 
Patient recruitment and serum sample collection 
Research ethical committee (REC) approval was obtained and all patients provided 
fully-informed, written consent. Patients with asymptomatic, infra-renal AAA were 
recruited from vascular clinics at HEFT and SWBH. Following skin preparation with 
an alcohol-based antiseptic, whole blood was drawn from an antecubital fossa vein 
using a tourniquet, Vacuette® Multi-Sample Blood Collection Needles (21G-green) 
and Vacuette® Standard Tube Holders into multiple Vacuette® Z Serum Clot 




Tubes were inverted 8 times to allow mixing and the whole blood permitted to clot at 
RT over 30 minutes prior to transfer, on ice, to the HBRC. Standard HRBC operating 
procedures were used to process and store samples. Specifically, within 6 hours of 
specimen collection, samples were centrifuged at room temperature (RT) for 10 
minutes at 4600RPM and then stored at -80C for later batch analysis. 
Measurement of IL-1α 
From the work in Chapter 7, we decided to utilise the Boster immunoassay for the 
purpose of our main analysis as it had provided the most dynamic range of results 
which were comparable across both serum methodology studies. Serum IL-1a was 
thus measured using a single batch (no.111945418712) of Boster immunoassay kits 
(EK0389, Boster Biological Technology Co. Ltd., Fermont, CA) according to the 
manufacturer’s instructions. Microplates were loaded with manufacturer’s standards 
and undiluted serum samples in triplicate. Optical density (OD) was measured using 
plate spectrophotometry at 450nm. Endpoint absorbance was measured on a BioTek 
Synergy
®
 multi-detection microplate reader utilising KC4
®
 v3.4 software. IL-1α 
titres were calculated against standard curves generated from each assay using 
reference concentrations supplied by manufacturers. OD readings were converted to 
units (pg/ml) with GraphPad PRISM v5.0. Sample results which fell below the 
detection limit of the assay were considered to have undetectable levels and assigned 
the value of 0pg/ml. 
Measurement of AAA size and morphology 
AAA MAPD was recorded by means of US on the date of serum sampling. Patient 
records were reviewed and in cases where CT-imaging was performed within ±3-
months of serum sampling, or where AAA CT size was ±5mm of US size, volume 




iNtuition software (TeraRecon, San Mateo, Calif, USA). In patients where suitable 
CT imaging was available, morphological characteristics were calculated by first 
using the workstation software to draw a centre line through the AAA, then 
individual parameters were measured by manually determining cut-off points within 
the scans such as ‘lowest renal artery’, ‘aortic bifurcation’ and so forth. An example 






Figure 9a. Example case of TeraRecon software used to calculate morphological 
aneurysm features in patients with available CT angiogram (CTA) imaging.  






Figure 9b. Reconstructed stretch view of an example aorta used to calculate 
AAA morphological features.  
This allows length measurements from the lowest renal artery (A) to the aortic 





Figure 9c. Demonstration of example patient AAA morphological measurements 
using the aortic stretch view.  
The use of dedicated software (in this case provided by TerraRecon) allows detailed 
assessment of aortic lengths as well as volumetric measurements (in cm
3
) of the 
vessel using automatic 3-dimensional reconstructions 
A~B = measurement from lowest renal artery to aortic bifurcation, RCIA = right 





Measurement of AAA growth rates 
Retrospective interrogation of a prospectively gathered AAA surveillance database 
was performed to obtain growth rates in those patients who had at least two scans. In 
total, 890 AAA measurements were analysed (783 US, 107 CT).  The mean (range) 
duration of follow-up was 61 months (0 to 185 months), with a mean (range) 9.2 
scans per person (2 - 34). Data from the first and last scans were used to calculate 
absolute (mm) change in MAPD and absolute (mm/year) change in MAPD over 
time. Negative growth rates between serial scans were not automatically excluded.  




Since IL-1α titres were highly skewed, they were log10-transformed, after adding one 
to all values to remove zeros.  The relationship between serum IL-1α levels and AAA 
size and growth rates was investigated using Spearman’s rank correlation 
coefficients. In addition, regression models were produced, with log10IL-1α set as the 
independent variable. 
The subgroup of patients who had received CT scans were then analysed in further 
detail. Spearman’s correlation coefficients were produced to test the relationship 
between IL-1α titres and a range of morphological AAA-related factors. Due to the 
high number of patients with undetectable IL-1α, the analysis was also performed 
with these patients excluded. Bonferroni or Šidák corrections were not made to adjust 
the p-values when performing multiple comparisons, so it is possible that some of the 
results obtained occurred simply through chance alone. 
In addition, the patients with undetectable levels were compared to those with 




factors, and Mann-Whitney tests for non-parametric data. The demographics of 
patients in the study were then compared to those in the previously published pilot 
study using the same approach.  
All analyses were performed using IBM SPSS Statistics 22 (IBM Corp. Armonk, 
NY), with p<0.05 deemed to be indicative of statistical significance. 
Results 
Serum IL-1α was measured in 101 patients (90 men) of mean (SD) age 74 (±7.0) 
years with asymptomatic infra-renal AAA. There was no statistically significant 
difference in mean (SD) age (years) between men (74±7.1) and women (77±6.6) (p = 
0.180, t-test). Median (Q1-Q3) IL-1α was 0.57 (0.00-4.91) pg/ml.  
IL-1α was detectable in 63 (62.4%) patients (58 men) of mean (SD) age 74 (±7.2) 
years with mean (range, [SD]) MAPD of 46 (32-70, [±9]) mm. There was a 
significant age difference between men and women in this group, with women being 
older than men (mean, [±SD] 81 [±4.7] years vs. 73 [±7.1] respectively, p = 0.020). 
Mean (SD) AAA MAPD in this group was 45 (±9) mm for men and 51 (±11) mm for 
women. This difference was not statistically significant (p = 0.168, t-test). Median 
(Q1-Q3) IL-1α titre was 3.26 (0.80-19.1) pg/ml.  
IL-1α was undetectable (0pg/ml) in 38 (37.6%) (32 men) patients of mean (SD) age 
74 (±6.9) years with AAA of mean (range, [SD]) MAPD of 46 (30-71, [10]) mm. 
There was no significant difference in age (p = 0.905), gender (p = 0.260) or MAPD 
(p = 0.879) between patients with detectable and undetectable IL-1α (t-test), and the 




Relationship between IL-1α and MAPD 
Of the 101 patients, 48 had AAA <45mm, 41 had AAA 45 to 55mm, and 12 had 
AAA>55mm. Mean (range, [SD]) MAPD as measured by US on the day of serum 
sampling was 46 (30-71, [±9]) mm. There was no statistically significant difference 
in MAPD between men and women in this group (p = 0.816, t-test).  
Overall, there was no statistically significant relationship between IL-1α and MAPD 
as measured by US on the day of IL-1α serum sampling (R-squared = 0.002, p = 
0.649) (Figure 10). 
Considering just those patients with detectable IL-1α, there was no statistically 







Figure 10. Relationship between MAPD (mm) as measured on US and log10 
serum IL-1α levels (pg/ml) in 101 patients with asymptomatic, infra-renal AAA  
The line on the graph is based on a regression model using the resulting variable, 
which found that a one log (i.e. ten-fold) increase in IL-1α was associated with a 





Relationship between IL-1α and AAA morphology on CT  
CT scans were available in 28 patients (24 men) of mean (SD) age of 74 (±7.1) years 
(74 (±7.2) for men and 72 (±7.2) for women). All CT scans were performed for non-
AAA related reasons. Internal morphological AAA features recorded from CT 
imaging and median IL-1α titres are shown for those with, and without, detectable 
IL-1α in Table 13. Spearman’s rank correlations were performed to establish 
relationships between IL-1α and morphological features. The only significant 
difference was detected for RCIA length (p = 0.045), which was greater in patients 











Men (%) 24 (86%) 13 (100%) 11 (73%) 0.102
#
 
Mean age in years (±SD) 74 (±7.2) 72 (±7.5) 75 (±6.7) 0.385* 
Median (Q1-Q3) IL-1α 
(pg/ml) 
0 (2.64) 3.16 (33.4) - - 
Mean AAA maximum AP 
diameter on US [±SD] 
(mm) 
50 [±10] 51 [±11] 49 [±10] 0.542* 
Mean AAA maximum AP 
diameter on CT [±SD] 
(mm) 
53 [±11] 51 [±10] 54 [±12] 0.457* 
Aortic length (mm) 126 (93-172) 126 (103-155) 122 (93-172) 0.394 
LCIA length (mm) 65 (34-100) 65 (34-100) 63 (45-88) 0.940 
RCIA length (mm) 63 (43-83) 51 (43-83) 65 (48-74) 0.045 
Aortic sac volume (cm
3
) 180 (48.7-539.0) 196 (71.0-394.0) 177 (48.7-539.0) 0.381 




90.0 (26.2-157.0) 76.6 (46.0-157.0) 90.8 (26.2-98.2) 0.717 
LCIA sac volume (cm
3
) 17.4 (5.8-53.7) 16.1 (5.8-53.7) 19.9 (7.5-36.2) 0.138 




7.3 (2.2-35.9) 7.1 (2.2-35.9) 8.0 (2.5-20.1) 0.202 
RCIA sac volume (cm
3
) 18.0 (5.7-71.0) 18.5 (8.8-40.1) 18 (5.7-71.0) 0.899 




9.5 (2.4-26.6) 8.4 (3.2-36.6) 10.2 (2.4-16.8) 0.486 




83.1 (22.4-441.0) 88.3 (25.4-322.0) 82.4 (22.4-441.0) 0.650 




9.4 (3.6-17.8) 9.2 (3.6-17.8) 9.4 (4.3-14.1) 0.467 




8.2 (3.3-54.2) 7.8 (4.6-25.2) 8.7 (3.3-54.2) 0.569 
Table 13. Internal architectural AAA features and median IL-1α titres recorded 
from 28 patients with available imaging. P-values result from comparison 
between detectable IL-1α and undetectable IL-1α groups 
Results are described as median (range), unless stated otherwise. SD=standard 
deviation, Q1 = 1st quartile, Q3 = 3rd quartile 
All p-values calculated by Mann-Whitney U unless otherwise indicated, p<0.05 
(bold) taken to be significant  
#






Aortic and common iliac morphological features 
Aortic length was defined as length (cm) from the lowest renal artery to the aortic 
bifurcation and common iliac artery (CIA) length was defined from the aortic 
bifurcation to the CIA bifurcation. The relationship between IL-1α and a range of 
aortic and CIA morphological features was investigated, including length, sac and 
luminal volumes and aortic thrombus volume. No significant correlation between IL-
1α serum titres and any of these factors was found (Table 14), although the 
correlation between RCIA length and IL-1α was negative and close to significance, 






All patients (N=28) Detectable IL-1a (N=13) 
 
Rho p-Value Rho p-Value 
Aortic length (mm) 0.205 0.296 0.342 0.253 
Aortic sac volume (cm
3
) 0.192 0.329 0.140 0.648 
Aortic luminal volume (cm
3
) 0.046 0.818 0.517 0.070 
Aortic thrombus volume (cm
3
) 0.027 0.891 -0.182 0.553 
Left CIA length  (mm) -0.011 0.958 0.014 0.966 
Left CIA luminal volume (cm
3
) -0.193 0.356 0.278 0.408 
Left CIA sac volume (cm
3
) -0.244 0.241 0.116 0.733 
Left CIA thrombus volume (cm
3
) -0.130 0.534 0.077 0.821 
Right CIA length (mm) -0.364 0.067 -0.161 0.617 
Right CIA luminal volume (cm
3
) -0.053 0.798 0.405 0.191 
Right CIA sac volume (cm
3
) 0.057 0.781 0.413 0.182 
Right CIA thrombus volume (cm
3
) -0.073 0.724 0.088 0.787 
Table 14. Relationship between serum IL-1α and morphological AAA-related 
features as measured on CT-imaging for all patients with available CT-imaging 
(n=28) and those with detectable serum IL-1α titres (n=13) 





Aortic thrombus volume 
There was no evidence of a significant relationship between IL-1α and absolute (p = 
0.891) or relative (thrombus volume / sac volume) aortic thrombus volume (p = 
0.967). 
Relationship between IL-1α and changes in AAA diameter 
Growth rate data were available in 97 patients (87 men) of mean (SD) age 74 (±7) 
years at the time of first scan. Mean MAPD (range) at first and last scans were 39 (24 
- 69) mm and 51 (31 - 78) mm respectively. Mean (range) absolute increase in 
MAPD was 11 (0 - 41) mm. Median (range) absolute AAA growth rate was 
1.9mm/year (0 - 69). No statistically significant relationship was detected between 
IL-1α and absolute AAA increase in MAPD (rho: -0.127, p = 0.214) or absolute 
growth rate (mm/year) (rho: -0.123, p = 0.230). 
Comparison of study results against published pilot study 
Comparison of our results between the previously published pilot study (137) 
demonstrated no statistical difference in patient age (mean 80 [±5] years, t-test p = 
0.168). However, in the pilot study the AAA were significantly larger (mean 68mm 
[±14], t-test p = 0.039), and four were juxta-renal. Comparison of the 28 patients in 
this study with the pilot study data demonstrated no statistically significant difference 
in aortic ILT-volume (Mann-Whitney, p = 0.160). Performing a sub-group analysis 
of our results on the basis of the patient demographics described by Yates et al still 
returned a non-significant result (p=0.343), although the effect was in the correct 
direction (Figure 11). Although the pilot study did not specifically analyse titres 




juxta-renal AAA, most likely due to small patient numbers, we have not been able to 






Figure 11. Patients limited to pilot study paper. i.e.: those pre-op with infra-
renal or juxta-renal AAA sized between 54mm and 100mm (inclusive) (n = 
34pts).  
The line on the graph is based on a regression model with the Log10 of IL-1α as a 
predictor. This found that a one log (i.e. ten-fold) increase in IL-1α was associated 







The natural history of AAA, and in particular the factors influencing progression, 
growth and risk of rupture, remain a focus of intense research interest. Identification 
of circulatory biomarkers which could be used as an adjunct, or alternative, to current 
predominantly size-based surveillance and intervention strategies are of particular 
interest. Although there is a relatively large published body of work on AAA 
biomarkers and the role of IL-1α in cardiovascular disease, there is very little 
information on IL-1α in patients with AAA. In this study we sought to examine the 
relationship between IL-1α and AAA MAPD and morphological features in a large 
cohort of patients with asymptomatic, infra-renal AAA and established that serum 
IL-1α concentrations are detectable in most (62.4%), patients. 
IL-1α is a pro-inflammatory cytokine that is largely undetectable in health but is 
present within many cell-lines and released in response to cell-damage.(189) 
Additionally, it has been shown that macrophages within the intima of atherosclerotic 
arterial lesions produce IL-1α.(190)  AAA is a chronic inflammatory condition, 
characterised by atherosclerosis, with increased expression of both inflammatory 
cells within the aneurysmal wall, and elevated serum pro-inflammatory 
cytokines.(191,192) Cytokines such as MMPs and Insulin-like Growth Factor 1 
(IGF-1) have been shown to correlate with AAA size and growth rate, and as such 
have been postulated to be potential biomarkers of AAA development.(82,193–195)    
In light of the above, it is reasonable to hypothesize that IL-1α may have a role in the 
development and progression of AAA. Indeed, we have previously reported a 
significant relationship between AAA diameter and serum IL-1α levels in a small 
cohort of AAA patients and that EC activation in vitro in response to serum from 




However, in this larger study we have been unable to demonstrate a significant 
relationship between IL-1α and AAA across a range of pre-operative MAPD as 
measured by US or to reproduce the data from the pilot study of 17 patients with 
infra- and juxta-renal AAA which showed a significant association between IL-1α 
and MAPD on US.(137) 
Comparison of current data against pilot study data demonstrated no significant 
difference in patient age or ILT volume. However, the patients recruited at that time 
were older (mean 80 years, range 69-88years) with larger AAA (mean 6.6cm, range 
5.4-10cm) AAAs, and the sample size (n=17) much smaller. Additionally, our pilot 
study reported much higher levels of serum IL-1α (5-100pg/ml) which we have been 
unable to replicate. Nevertheless, even performing a sub-group analysis of our results 
on the basis of the patient demographics described by Yates et al still returned a non-
significant result (p = 0.343) when looking at AAA MAPD and serum IL-1α  
(Figure 8). One possible explanation of this is the use of a different immunoassay to 
measure IL-1α. Inconsistencies in ELISA immunoassays may, in part, account for the 
differences in results found between this study and the pilot work. However, we 
consolidated our methodology ahead of this work and believe the Boster 
immunoassay to be robust in its abilities to detect and measure IL-1α.(196) 
Nevertheless, variability between manufacturers’ ELISA assays is known to 
exist.(184) The large number of patients where IL-1α was undetectable (0pg/ml) may 
have masked an underlying relationship between AAA size, morphology, growth and 
IL-1α. However, no relationship was found even with these “IL-1α negative” patients 
excluded from the analysis. 
The lack of statistically significant findings may also be as a result of the low 




power calculation found that the minimal detectable correlation coefficient was 0.27 
for the analyses of the whole cohort (n = 101), and 0.48 for the analysis of the subset 
of patients with CT scans (n = 28) at 80% power and 5% alpha. Hence, weak to 
moderate correlations between factors could have been missed (false negative errors). 
Despite this, the majority of correlation coefficients detected were small (<0.2), and 
so unlikely to represent meaningful relationships.  
ILT activity and extra-cellular aortic wall degradation and adventitial abnormalities 
are recognised features of AAA disease. However, although there is experimental 
evidence to suggest that ILT influences the inflammatory process in AAA, this has 
not been confirmed by clinical studies.(197–200,67,62) Our measurements of 
internal AAA morphological features (aortic and common iliac artery lengths) are in-
keeping with published results (201), but we have been unable to demonstrate a 
significant relationship between aortic or iliac aneurysmal size and IL-1α. This 
suggests that the luminal and sac volumes do not affect the pro-inflammatory AAA 
state, at least through an IL-1α-mediated pathway.  
Although the relationship between IL-1α and MAPD observed in our pilot study may 
represent chance findings, it is harder to discount the observation that EC activation 
in vitro in response to serum from the AAA patients was blocked by anti-IL-1α 
antibodies while antibodies against the other inflammatory markers studied had no 
effect.(137) One could argue that the small sample size in the pilot study (n = 17) and 
the positive results found in that group were fortuitous. However, the small sample 
size would not necessarily make it any more likely of making chance positive 
findings in fact, it would be potentially less likely given the reduction in statistical 




and to that end we are unable to explain the pilot study’s results given our own 
negative results.  
We have shown that the majority of patients with AAA have detectable serum IL-
1α., but the exact nature of the IL-1α profile abnormalities seen remain to be 
determined. 
 As IL-1α is an important component of the systemic inflammatory response, our 
results may, therefore, simply be reflecting an association between IL-1α and a 
generalised systemic pro-inflammatory, pro-thrombotic state which may be related to 
the presence of AAA in some patients and to other disease processes in others. At 
present, the reasons for this are unclear and the subject of on-going studies, including 
determining the relationship between IL-1α, co-morbidities and other markers of 
inflammation to establish what the biological and clinical significance of these high 
serum IL-1α levels may be in terms of cardiovascular outcomes in general and, more 





Chapter 9: Study 2, looking at serum IL-1α as a marker of chronic 
inflammation in patients with asymptomatic AAA 
Aims: To investigate the relationship between serum IL-1α, co-morbidity, smoking 
status, and BMT in patients with asymptomatic, infra-renal AAA. 
Introduction 
AAA usually remain asymptomatic until complications develop, most commonly 
rupture. MAPD is currently believed to be the best predictor of rupture and so is the 
variable most often used to select patients for OR or EVAR.(36,37,42,43) 
Aortic aneurysmal disease is widely considered to be a chronic inflammatory 
condition that is separate from, but which often co-exists with, atherosclerosis due to 
shared risk factors, in particular smoking and high blood pressure.(188)  
IL-1α is a pro-inflammatory cytokine that is not normally detectable in the 
circulation (127) and which has been previously linked with cardiovascular and 
aortic diseases.(142,134,103,89,94)  
Several groups, including our own, have previously demonstrated that patients with 
AAA have elevated serum markers of inflammation and coagulation in association 
with a systemic pro-thrombotic, pro-inflammatory diathesis.(79–82) It has been 
hypothesised that these moieties may originate from within the AAA wall and/or 
ILT. 
Alternatively, or additionally, these factors may enter the systemic circulation as a 
result of other inflammatory vascular and non-vascular diseases that frequently co-
exist in AAA patients. Other factors such as smoking and drug treatment may also 




It remains unclear whether AAA progression is primarily due to localised 
biomechanical (blood pressure, aneurysm morphology) or biological factors within 
the aneurysm wall/thrombus and to what extent other chronic inflammatory 
processes occurring outside the aorta contribute to AAA growth and rupture. 
An intervention strategy based on biomechanical factors (size) alone may leave 
patients with small, but nevertheless ‘biologically active’, AAA unprotected from 
rupture whereas patients with large but biological quiescent AAA may be offered 
unnecessary surgery.  
There is therefore an urgent need to identify better predictors of rupture so that 
available health care resources can be used in the most clinically and cost-effective 
manner. 
We have previously demonstrated that some patients with AAA have raised serum 
IL-1α levels and that endothelial cell (EC) activation in vitro, in response to serum 
from these AAA patients, is blocked by anti-IL-1α antibodies.(137) 
The aim of this study was to investigate the relationship between serum IL-1α, co-
morbidity, smoking status, and BMT in patients with asymptomatic, infra-renal 
AAA. 
Methods 
Patient recruitment and serum sample collection 
Research ethical committee (REC) approval was obtained (reference 12/WM/0204) 
and all patients provided fully-informed, written consent.  
A cohort of 101 patients with asymptomatic infra-renal AAA was recruited from 




Following skin preparation with an alcohol-based antiseptic, whole blood was drawn 
from an antecubital fossa vein using a tourniquet, Vacuette® Multi-Sample Blood 
Collection Needles (21G-green) and Vacuette® Standard Tube Holders into multiple 
Vacuette® Z Serum Clot Activator tubes (Greiner Bio-One, Kremsmünster, Austria). 
Tubes were inverted 8 times to allow mixing and the whole blood permitted to clot at 
room temperature (RT) over 30 minutes. They were then transferred, on ice, to a 
regional biobank facility: the HBRC. 
Standard HBRC operating procedures were used to process and store samples. 
Specifically, within 6 hours of specimen collection, samples were centrifuged at RT 
for 10 minutes at 4600RPM and then stored at -80C for later batch analysis. 
Measurement of IL-1α 
Serum IL-1α was measured using a single batch (no: 111945418712) of Boster 
ELISA immunoassay (Cat no: EK0389, Boster Biological Technology Co. Ltd., 
Fermont, CA) according to the manufacturer’s instructions.  
Microplates were loaded with manufacturers’ standards and undiluted serum samples 
in triplicate. Optical density (OD) was measured using plate spectrophotometry at 
450nm. Endpoint absorbance was measured on a BioTek Synergy
®
 multi-detection 
microplate reader utilising KC4
®
 v3.4 software.  
IL-1α titres were calculated against standard curves generated from each kit using 
reference concentrations supplied by the manufacturer. OD readings were converted 
to units (pg/ml) with GraphPad PRISM v5.0. Sample results which fell below the 
detection limit of the assay were considered to have undetectable levels and assigned 




Coding of co-morbidity 
Patient records were reviewed for the presence, or absence of co-morbidities. A 
diagnosis of hypertension (HT) was recorded if the patient was receiving anti-
hypertensive medication; ischaemic heart disease (IHD) if there was record of a past 
myocardial infarction, or angina; cerebrovascular accident (CVA) if they had a 
history of transient ischaemic attack, or stroke; diabetes mellitus (DM) and chronic 
obstructive pulmonary disease (COPD) if they were recorded as having and/or on 
medication for these diagnoses; hypercholesterolaemia if they had a record of 
elevated serum cholesterol and/or were on a cholesterol-lowering agent; peripheral 
arterial disease (PAD) if the diagnosis had been made by a vascular specialist based 
on symptoms, clinical examination or imaging (e.g. duplex or angiography); and 
atrial fibrillation (AF), hypothyroidism and gout if they had been recorded as having 
and/or were on appropriate medication for these diagnoses. Smoking status, and 
history of coronary artery bypass grafting (CABG), deep venous thrombosis (DVT) 
and malignancy was confirmed at time of sampling. 
BMT was defined as the use of an anti-platelet and statin therapy. Confirmation of 
BMT regime was recorded at the time of serum sampling. Anticoagulation therapy 
(e.g. with warfarin) was also noted.  
Analysis of other serum markers of inflammation 
Patient records were interrogated for additional markers of inflammation (neutrophil, 
lymphocyte eosinophil and platelet counts) taken within 3-months of serum sampling 
for IL-1α. C-reactive protein (CRP) was only available in 5 patients, so excluded 






Since IL-1α titres were highly skewed, they were log10-transformed after adding one 
to all values to remove zeros, with the resulting variable set as the covariate in the 
model. Patient age and AAA size were grouped to allow cross-comparison. Age 
groups were set as: ≤69 (n = 26), 70 ≥ n ≤ 74 (n = 26), 75 to 79 (n = 28) and ≥ 80 (n 
= 21) years. AAA sizes were grouped as ≤ 44 (n = 48), 45 to 55 (n = 41) and ≥ 56 (n 
= 12) mm. The relationships between serum IL-1α levels and co-morbidities, 
smoking status and BMT for cardiovascular disease and other markers of 
inflammation were investigated. Analyses were performed using the Mann-Whitney 
and Kruskal-Wallis tests and IBM SPSS Statistics 22 (IBM Corp. Armonk, NY). 
Results 
Serum IL-1α was measured in 101 patients (90 men) of mean (standard deviation, 
SD) age 73 (±7.0) years with non-operated, asymptomatic, infra-renal AAA. Patient 
demographics and co-morbidities are shown in Table 15. Overall, median (inter-
quartile range, IQR) serum IL-1α was 1.00pg/ml (4.91pg/ml). There was no 
statistically significant relationship between serum IL-1α levels and patient gender (p 
= 0.598) or age (p = 0.620). IL-1α was detectable in 63 (62.4%) patients (58 men) of 
mean (SD) age 74 (±7.1) years with AAA of mean (range, [SD]) AP diameter of 46 
(32–70, [±7]) mm. In this group, median (IQR) serum IL-1α was 3.26 (18.27) pg/ml. 






















Table 15. Patient co-morbidities and aneurysm-related risk factors as recorded 
at time of IL-1α serum sampling 
Values in (parentheses) are % of group  
HT: hypertension; IHD: ischaemic heart disease; CABG: coronary artery bypass 
graft; CVA: stroke; CCF: congestive cardiac failure; AF: atrial fibrillation; DM: 
diabetes mellitus; COPD: chronic obstructive pulmonary disease; DVT: deep venous 
thrombosis; PVD: peripheral vascular disease; BMT: best medical therapy 
  
   
Group size [n] 101 (%) 
Co-morbidity [n] (%)  
HT 67 (66.3) 
IHD 36 (35.6) 
CABG 10 (9.9) 
CVA  8 (7.9) 
CCF 3 (3.0) 
AF 9 (8.9) 
DM 17 (16.8) 
COPD 14 (13.9) 
Hypercholesterolaemia 23 (22.8) 
DVT 4 (4.0) 
PVD 5 (5.0) 
History of active/past malignancy 10 (9.9) 
Hypothyroidism 3 (3.0) 
Gout 5 (5.0) 
Smoking status  
Never 13 (12.9) 
Ex-smoker 63 (62.4) 
Active smoker 24 (23.8) 
Data missing 1 (1.0) 
Best medical therapy (‘BMT’)  
No BMT 8 (7.9) 
Aspirin/Statin 70 (69.3) 
Aspirin only 2 (2.0) 
Statin only 10 (9.9) 
Warfarin/Statin 7 (6.9) 
Other combination 2 (2.0) 




Relationship between IL-1α and co-morbidities 
There was no significant relationship between IL-1α and any of the co-morbidities 
analysed, smoking status or BMT regime, results are shown in Table 16.  
Relationship between IL-1α and other serum markers of inflammation 
Additional serum markers for active or chronic inflammation were available in 69 
(68.3%) patients (60 men) of mean age (range, [SD]) 74 (56-87, [±7]) years and 
mean (range, [SD]) AAA MAPD (range, [SD]) 46 (30-71, [9]) mm. IL-1α was 
detectable in 45/69 (65.2%) patients (40 men) of mean (SD) age 74 (±7.1) years and 
mean (range, [SD]) AAA MAPD 45 (32-70 [±9]) mm. In this group, median (IQR) 
serum IL-1α was 2.05 (13.82) pg/ml. IL-1α was undetectable in 24 (34.8%). 
There was no statistically significant relationship between serum IL-1α titres and 
patient neutrophil (p = 0.726), lymphocyte (p = 0.545), eosinophil (p = 0.747) or 
platelet (p = 0.585) counts in the cohort overall (Figures 10 – 15). There was no 
statistically significant relationship between serum IL-1α titres and patient neutrophil 
(p = 0.841), lymphocyte (p = 0.935), eosinophil (p = 0.935) or platelet (p = 0.488) 





Table 16. Relationship between patient co-morbidity and IL-1α 
Analyses performed using Mann-Whitney U test unless otherwise specified. 
*
 Kruskal-Wallis test. 
HT: hypertension; IHD: ischaemic heart disease; CABG: coronary artery bypass 
graft; CVA: stroke; CCF: congestive cardiac failure; AF: atrial fibrillation; DM: 
diabetes mellitus; COPD: chronic obstructive pulmonary disease; DVT: deep venous 
thrombosis; PVD: peripheral vascular disease; BMT: best medical therapy 
  







Co-morbidity     
HT 1.0 0-1267.99 0.810 
IHD 0.33 0 - 1110.51 0.235 
CABG 3.31 0 - 1110.51 0.222 
CVA  0.16 0 - 1110.51 0.397 
CCF 0 0-19.24 0.618 
AF 2.46 0-305.29 0.123 
DM 0.64 0-305.29 0.845 
COPD 2.86 0-305.29 0.201 
Hypercholesterolaemia 0.03 0-1267.99 0.322 
DVT 2.54 1.09-85.77 0.190 
PVD 0 0-7.0 0.504 




Hypothyroidism 0 0-0.18 0.167 






































































The natural history of AAA, and in particular the factors influencing progression and 
risk of rupture, remain a focus of intense research interest. One line of study focuses 
on the identification of circulatory biomarkers which could be used as an adjunct, or 
alternative, to current, predominantly size-based, surveillance and intervention 
strategies.  Such biomarkers may also provide a biological signal that may lead to 
novel drug therapies that will prevent AAA development, growth and rupture.  
The current study arises from previous work which demonstrated that some patients 
with AAA have raised serum IL-1α levels (a cytokine not normally detectable in 
health) and that EC activation in vitro, in response to serum from these AAA patients 
is blocked by anti-IL-1α antibodies.(137) The question is whether the IL-1α detected 
in AAA patients emanates from the AAA (aortic wall and/or ILT) or whether it 
reflects other inflammatory processes that frequently co-exist with the AAA in this 
patient group, or both.(197–200,67,62)  
In this study, we have again shown that serum IL-1α levels are raised in some, but 
not all, patients with AAA. However, we have not been able to demonstrate a 
significant relationship between IL-1α and co-morbidity, smoking status and BMT or 
other simple markers of inflammation. 
Interestingly, however, there was a suggestion that those patients who were receiving 
warfarin for AF or DVT had higher IL-1α titres than those who were not. Whether 
there is a link between a pro-thrombotic tendency, requiring warfarin therapy, and 
raised IL-1α, is the subject of further on-going study. Also of interest was the lack of 
a relationship between IL-1α and smoking status, with levels tending to be higher in 




current smokers when one might have supposed that active smokers would have 
higher levels due to the known low-grade systemic inflammatory response, which 
can persist up to twenty years after cessation.(202)  
In conclusion, the current study suggests that the markedly elevated levels of IL-1α 
observed in about two-thirds of patients with AAA appear not to be related to extra-
aortic patient characteristics or co-morbidities. In other words, it appears likely that 
the IL-1α observed in this group is being generated within the AAA, either from the 
aortic wall and/or the ILT. The relationship between IL-1α and the characteristics of 







Chapter 10: General discussion 
The central hypotheses of this Thesis are that IL-1α can be utilised as a surrogate 
marker for disease progression and risk of rupture in those with asymptomatic, infra-
renal AAA. Specifically, on the basis of previously published pilot work, we 
hypothesised that IL-1α titres are elevated in those with AAA, and that these titres 
correlate with AAA size, morphology and patient-dependent factors such as co-
morbidity and to that end, IL-1α can be used as a surrogate marker to identify those 
most likely to need surgical intervention.  
These hypotheses have been tested robustly, having first undertaken a thorough 
methodology study assessing the current IL-1α immunoanalysis assays commercially 
available on the market to measure IL-1α. I can conclude that, at present, although 
IL-1α clearly participates in the AAA pathway as most patients with AAA have 
elevated titres, there is insufficient evidence to say that it is a clinically effective or 
useful surrogate marker of biological activity.  
It took the best part of 18 months to conduct the methodology study, and identify an 
immunoassay sufficiently reliable to conduct the subsequent analyses. There were 
two main reasons for this. Firstly, we had strong faith in the methodology used for 
the published results from the pilot study, and so did anticipate a problem when it 
came to the initial immunoanalysis. The disappointing results from our initial run 
were a real obstacle to us progressing with the proposed project work. Our 
acceptance of the results in the pilot study meant that we were caught unawares by 
our negative results, and were then obligated to spend time analysing the possible 
discrepancies between the pilot work and our own patient analysis to try to establish 




identified any obvious reason why processing our samples via HBRC should have 
resulted in negative titres, as IL-1α has been found to be a relatively stable molecule. 
Additionally, in our minds, we did not feel there would be great variation amongst 
different immunoassays, all of which are marketed as being reliable in detecting 
serum IL-1α. We were thus satisfied in using the assay most commonly used by the 
CIS, the Bio-Rad Bio-Plex Pro assay in our initial run. The reason why, in our run, 
CIS used the Bio-Rad immunoassay, and not the Millipore Milliplex MAP kit was 
that my predecessor had found the positive IL1-α signal during a fortuitous ‘fishing 
screen’ of various cytokines in his AAA patient cohort. When analysing for IL-1α 
alone, the CIS recommended the Bio-Rad Bio-Plex Pro kit as it was the measuring 
platform they used most commonly for IL-1α. Again, because we had no idea at that 
point of the differences between kits, we were satisfied that it should not pose any 
real problems. Our negative results were disappointing, and the purchasing of new 
Millipore and Bio-Rad kits, identifying my predecessor’s stored samples and running 
both together was a frustrating process which added significant delays to our work 
progressing. The (again) disappointing results from these re-runs also highlighted an 
interesting result; although we could not confirm how many freeze/thaw cycles my 
predecessors samples had been through, logically we could see no reason why they 
would have been subjected to more than three or four at most. As the literature 
suggested that IL-1α is relatively stable up to six freeze/thaw cycles, we were unable 
to explain the differences in titre values found, other than to attribute them to 
possible degradation of IL-1α as a result of prolonged storage at -80C.(173)  
Communication with Merck Millipore enquiring as to whether they had changed 
their immunoassay between the pilot study run in 2009 and our yielded no useful 




have contained different antibodies, so it is not always possible to compare data” and 
further enquiries to clarify the nature of antibody differences were unsuccessful. 
Hence we can but assume that there was a difference, and that this in part must have 
been a cause of the discrepancies seen between our results and the pilot study.   
The main empirical findings of this work are chapter specific, and were summarised 
within the respective chapters:Chapter 6,  Chapter 8 and Chapter 9. Using the 
findings from these two studies to answer the Thesis hypotheses, we can say that 
there is a need to identify a better, more cost-effective means of monitring AAA 
progression and need for surgical intervention in patients as only 20.1% of a cohort 
of 692 patients in surveillance at HEFT proceeded to elective AAA repair, despite 
5363 scans being performed as part of the surveillance protocol. This represents a 
huge potential waste of resources.  
Our results show that current intervention strategies based on MAPD alone also leave 
a significant proportion of patients with AAA smaller than the current intervention 
threshold of MAPD ≥55mm unprotected from timely surgery, with 40.7% of patients 
with ruptured AAA had last recorded MAPDs less than 55mm. Although, in general 
those with AAA requiring intervention had faster AAA growth rates than those who 
did not this did not hold true for those who ruptured their AAA at sub-threshold 
MAPD size. Hence, these small, but clinically important sub-group of patients are 
not appropriately protected by a surveillance strategy based on MAPD alone. 
Additionally, analysis of various patient-related factors did not identify any that 
could be reliably used to predict rupture risk. This confirmed the need to identify 
other, biological, markers of AAA progression. 
Our work on IL-1α however demonstrated that although it is present in most (62.4%) 




morphological features, including ILT. Additionally, we did not find any meaningful 
correlation between it and patient-related factors, including other serum markers of 
inflammation.  
On the basis of this, we can therefore conclude that although the presence of IL-1α in 
patients in AAA remains undetermined, it cannot be said at present to be a suitable 
surrogate marker for AAA disease.  
Future studies 
Despite the fact that we initially struggled to find a reliable immunoassay to measure 
IL-1α in our serum samples, we believe that the Boster kit used provided us with 
sufficiently reliable and reproducible results to perform the work. There is some 
merit in continued investigation of the role IL-1α has in AAA disease, in particular 
the most logical step would be measuring it in those with a recorded positive pre-
operative titre in the post-operative period, to see whether surgical repair impacts IL-
1α values. Additionally, the source of IL-1α in those with positive titres merits 
further investigation with histological analysis of aortic wall and intra-luminal 
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